Necroptosis microenvironment directs lineage commitment in liver cancer by Seehawer, Marco
  
 
Necroptosis microenvironment directs 







der Mathematisch-Naturwissenschaftlichen Fakultät 
der Eberhard Karls Universität Tübingen 
zur Erlangung des Grades eines 
Doktors der Naturwissenschaften 










































Gedruckt mit Genehmigung der Mathematisch-Naturwissenschaftlichen Fakultät der 




Tag der mündlichen Qualifikation:  
Dekan: Prof. Dr. Wolfgang Rosenstiel  
1. Berichterstatter: Prof. Dr. Lars Zender 
2. Berichterstatter: Prof. Dr. Klaus Schulze-Osthoff 
Vorveröffentlichung der Dissertation 
 
Ergebnisse aus dieser Arbeit wurden mit Genehmigung der Mathematisch-
Naturwissenschaftlichen Fakultät der Universität Tübingen, vertreten durch die 
Mentoren der Arbeit, im folgenden Beitrag vorab veröffentlicht: 
 
M. Seehawer,  F. Heinzmann, L. D’Artista, J. Harbig, P.-F. Roux, L. Hoenicke, H. 
Dang, S. Klotz, L. Robinson, G. Doré, N. Rozenblum, T.-W. Kang, R. Chawla, T. 
Buch, M. Vucur, M. Roth, J. Zuber, T. Luedde, B. Sipos, T. Longerich, M. 
Heikenwälder, X. W. Wang, O. Bischof and L. Zender (2018). "Necroptosis 
microenvironment directs lineage commitment in liver cancer." Nature 562(7725): 69-
75. 
 










Marco Seehawer 1 33 32 28 28 
Florian Heinzmann 1 15 26 19 18 
Luana D’Artista 2   5 4   
Jule Harbig 3   5 4   
Pierre-Francois Roux 4   5 4   
Lisa Hönicke 5   2     
Hien Dang 6   2     
Sabrina Klotz 7   2     
Lucas Robinson 8   2     
Grégory Dore 9   2     
Nir Rozenblum 10   2     
Tae-Won Kang 11   2     
Rishabh Chawla 12   2     
Thorsten Buch 13   2     
Mihael Vucur 14   2     
Mareike Roth 15   2     
Johannes Zuber 16     2   
Tom Lüdde 17   1     
Bence Sipos 18     2   
Thomas Longerich 19     2   
Mathias Heikenwälder 20   2     
Xin Wei Wang 21   2 2   
Oliver Bischof 22 1   5 3 
Lars Zender 23 51   28 51 
title of paper: 
Necroptosis microenvironment directs lineage commitment in liver 
cancer 
status in publication 
process: 
published 
Table of contents   3 
   
Table of contents 
Table of contents ................................................................................................................... 2 
Abbreviations ......................................................................................................................... 5 
Summary .................................................................................................................................. 7 
Zusammenfassung................................................................................................................ 8 
1. Introduction...................................................................................................................... 9 
1.1. Primary liver cancer .................................................................................................. 9 
1.1.1. Etiology and risk  factors........................................................................................... 9 
1.1.2. Diagnosis and treatment options .............................................................................10 
1.1.3. Molecular and cellular pathogenesis ........................................................................11 
1.2. Cell death in chronic liver disease ........................................................................ 13 
1.3. Role of epigenetic in cellular fate and cancer...................................................... 16 
1.4. Aim of the study....................................................................................................... 19 
2. Material and Methods ..................................................................................................20 
2.1. Material...................................................................................................................... 20 
2.1.1. Chemicals..............................................................................................................20 
2.1.2. Enzymes ...............................................................................................................20 
2.1.3. Kits........................................................................................................................20 
2.1.4. Buffers and solutions  ..............................................................................................21 
2.1.5. Antibodies..............................................................................................................22 
2.1.6. Oligonucleotides  ....................................................................................................23 
2.1.7. Plasmids................................................................................................................24 
2.1.8. Bacteria .................................................................................................................25 
2.1.9. Cell lines ................................................................................................................25 
2.1.10. Mouse strains  ........................................................................................................25 
2.2. In vivo experiments ................................................................................................. 25 
2.2.1. Mouse husbandry...................................................................................................25 
2.2.2. Hydrodynamic tail vein injection (HDTV) ..................................................................26 
2.2.3. In vivo liver electroporation (Epo) ............................................................................26 
2.2.4. Bile duct ligation .....................................................................................................26 
2.2.5. Liver perfusion .......................................................................................................26 
2.2.6. Subcutaneous tumor cell injection ...........................................................................27 
2.3. Histological methods .............................................................................................. 27 
2.3.1. Hematoxylin/eosin (H&E) and immunohistochemistry staining (IHC)  ..........................27 
2.3.2. Native fluorescence staining ...................................................................................28 
2.3.3. Immunofluorescence staining (IF) on paraffin slides  .................................................28 
2.3.1. Immunofluorescence staining (IF) on cells  ...............................................................28 
2.3.2. Terminal deoxynucleotidyl transferase dUTP nick  end labeling (TUNEL) ....................28 
2.3.3. Laser capture microdissection (LCM).......................................................................29 
2.4. Cell culture ............................................................................................................... 29 
2.4.1. Standard cell culture...............................................................................................29 
2.4.2. Establishing primary cell lines from tumors ...............................................................29 
2.4.3. Production of retroviral particles  ..............................................................................30 
4  Table of contents 
   
 
2.4.4. Stable transduction of cells .....................................................................................30 
2.4.5. Flow cytometry analysis ..........................................................................................30 
2.5. Molecular biology techniques ................................................................................ 31 
2.5.1. Plasmid preparation from bacterial cultures ..............................................................31 
2.5.2. Digestion of specific DNA fragments with restriction enzymes  ...................................31 
2.5.3. Dephosphorylation of DNA fragments ......................................................................31 
2.5.4. Ligation of DNA fragments ......................................................................................32 
2.5.5. Transformation of bacteria ......................................................................................32 
2.5.6. Polymerase chain reaction (PCR)............................................................................32 
2.5.7. Mutagenesis  ..........................................................................................................32 
2.5.8. Isolation of genomic DNA .......................................................................................33 
2.5.9. RNA Isolation.........................................................................................................33 
2.5.10. Measuring DNA and RNA concentration ..................................................................34 
2.5.11. Quantitative Real-time-PCR (qRT-PCR) ..................................................................34 
2.6. Biochemical methods ............................................................................................. 34 
2.6.1. Protein Isolation .....................................................................................................34 
2.6.2. Measuring protein concentration .............................................................................34 
2.6.3. Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) ...............34 
2.6.4. Western Blot ..........................................................................................................35 
2.7. Next Generation Sequencing (NGS) techniques ................................................. 36 
2.7.1. Whole exome sequencing (WES) ............................................................................36 
2.7.2. Assay for Transposase-Accessible Chromatin (ATAC)-seq .......................................36 
2.7.3. Microarray gene expression profiling .......................................................................36 
2.7.4. Chromatinimmunoprecipitation (ChIP)-seq ...............................................................36 
3. Results ............................................................................................................................38 
3.1. Hepatocyte-derived HCC and ICC can be induced by the same oncogenic 
drivers .................................................................................................................................. 38 
3.2. Lineage commitment in PLC is independent of somatic mutations ................. 42 
3.3. Physicochemical conditions of oncogene plasmid delivery method determine 
the tumor type ..................................................................................................................... 44 
3.4. Immune cell composition during the pre-tumorigenic phase does not impact 
tumor phenotype ................................................................................................................ 47 
3.5. Hepatocyte cell death influences tumor fate........................................................ 51 
3.6. Toll-like-receptors are necessary for lineage commitment in liver 
tumorigenesis ..................................................................................................................... 58 
3.7. Lineage commitment in liver tumorigenesis is epigenetically regulated ......... 59 
3.8. Prdm5 and Tbx3 are key regulators of PLC lineage commitment ..................... 63 
4. Discussion......................................................................................................................68 
5. Acknowledgements .....................................................................................................78 
6. References .....................................................................................................................79 
7. Appendix.........................................................................................................................90 
Abbreviations  5 
   
Abbreviations 
AFP alpha-fetoprotein  IRI ischemia-reperfusion injury  
AFP-L3 L3 fraction of alpha-fetoprotein  IR inverted repeats 
APAP acetaminophen K  cytokeratin  
ASH alcoholic steatohepatitis KO knockout 
aSMA alpha smooth muscle actin  LB  lysogeny broth  
ATAC Assay for Transposase-Accessible 
Chromatin 
LCM laser-capture microdissection 
ATP adenosintriphosphate  LPC  Liver progenitor cell  
BCL2 B-cell lymphoma 2 LPS lipopolysaccharide 
BDL bile duct ligation M  molar  
bp  base pair  MetOh methanol 
BSA  bovine serum albumin  min  minute  
C  Celsius  MLKL 
mixed-lineage kinase domain like 
pseudokinase  
CA 19-9 carbohydrate antigen 19-9  MOMP 
mitochondrial outer membrane 
permeabilization 
Casp caspase mRNA  messenger RNA  
CCA  Cholangiocarcinoma  n  number  
CCsgp19 CRISPR/Cas9-sg_p19 NaCl  sodium chloride  
cDNA  complementary DNA  NAFLD non-alcoholic fatty liver disease 
ChIP Chromatinimmunoprecipitation NASH  nonalcoholic steatohepatitis  
CIP   calf intestinal alkaline  phosphatase  NGS next generation sequencing 
CRISPR Clustered Regularly Interspaced Short 
Palindromic Repeats 
NGS  normal goat serum  
DAI DNA-dependent activator of IFN-
regulatory factors 
o/n over night 
DAMP 
damage associated molecular 
patterns 
OE overexpression 
DAPI  4',6-diamidino-2-phenylindole  p  p-value  
dCCA distal cholangiocarcinoma PBS  phosphate buffered saline  
DCP des-γ carboxyprothrombin  PBST  phosphate buffered saline with tween  
DMSO  dimethylsulfoxide  pCAA  perihilar cholangiocarcinoma 
DNA  deoxyribonucleic acid  PCR  polymerase chain reaction  
dNTP  2’-desoxynukleoside-5’-        
triphosphate  
PDAC pancreatic ductal adenocarcinoma 
e.g.  exempli gratia  PFA  paraformaldehyde  
EDTA  ethylenediaminetetraacetic acid  PKG phosphoglycerinkinase 
Epo in vivo electroporation PLC  primary liver cancer  
ER endosplamic-reticulum  PSC  primary sclerosing cholangitis  
EtOH ethanol PVDF polyvinylidene difluoride 




FCS  fetal calf serum  RA retinoic acid  
Fig  Figure  ref  reference  
gDNA  genomic DNA  RIPK 
receptor interacting serin/threonine 
protein kinase  
GFP green fluorescent protein RNA  ribonucleic acid  
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HNF  hepatocyte nuclear factor  TNFRSF 
tumor necrosis factor receptor 
superfamily  
HRP horseradish peroxydase TUNEL 
Terminal deoxynucleotidyl transferase 
dUTP nick end labeling 
HSC hepatic stellate cell  V volt 
ICC/iCCA intrahepatic cholangiocarcinoma WB western blot 
ICH Immunohistochemistry WES whole exomes sequencing 
IF  immunofluorescence  wt wildtype 
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Summary 
Primary liver cancer is a major health problem with markedly increasing incidence 
rates. It is mainly represented by hepatocellular carcinoma (HCC) and intrahepatic 
cholangiocarcinoma (ICC) which are quite different regarding their morphology and 
treatment options. Although both share many risk factors as chronic liver damage or 
inflammation and cirrhosis, the molecular determinants resulting in either HCC or ICC 
lineage are largely unknown.  
Here, using two different transposon-based liver cancer mouse models we show that 
both HCC and ICC can be induced by overexpressing the same oncogenes. 
Taking advantage of a lineage tracing mouse model we prove that both tumors are 
derived from adult hepatocytes. Lineage commitment is independent of somatic 
mutations but depends on the hepatic microenvironment in the pre-tumorigenic 
phase. While in an apoptotic milieu there is an outgrowth of HCC a necroptotic milieu 
determines ICC development. This is independent of the composition of infiltrating 
immune cells, however, it is associated with a specific cytokine signature. The 
specific cytokine signature can be reversed when inhibiting necroptosis chemically or 
genetically and is followed by a switch from ICC to HCC development.  
Epigenetic and transcriptomic analyses of cell lines isolated from hepatocyte-derived 
HCC or ICC driven by the same oncogene showed specific signatures for each tumor 
type. Integrative analyses of epigenetic and transcriptomic data revealed Tbx3 and 
Prdm5 as differentially regulated transcription factors which could also be found in a 
large cohort of human patients. Functional validation further showed that the interplay 
of Tbx3 and Prdm5 is sufficient to switch tumor lineage commitment from HCC to 
ICC. Finally, we identified downstream targets for both transcription factors which 
revealed quite converse downstream pathways highlighting the importance for their 
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Zusammenfassung 
Leberkrebs ist ein globales Gesundheitsproblem mit deutlich ansteigender Inzidenz. 
Das Hepatozelluläre Karzinom (HCC) und das Cholangiozelluläre Karzinom (ICC) 
sind die zwei am häufigsten vorkommenden primären Leberkrebstypen, welche sich 
sowohl in ihrer Morphologie als auch hinsichtlich ihrer Therapien sehr unterscheiden. 
Obwohl bekannt ist, dass beide gemeinsame Risikofaktoren, wie chronische 
Leberentzündung oder Zirrhose, haben, sind die genauen molekularen Ursachen zur 
HCC oder ICC Entstehung nicht bekannt. 
In dieser Studie konnte ich mithilfe von Transposon-basierten mosaiken 
Mausmodellen zeigen, dass sowohl HCCs als auch ICCs durch Überexpression 
derselben Onkogene induziert werden können. In einem „Lineage-Tracing“-Modell 
habe ich bewiesen, dass sich beide Tumorentitäten aus adulten Hepatozyten 
entwickeln können. Die Entwicklung des spezifischen Tumortyps ist unabhängig von 
somatischen Mutationen, jedoch ist sie abhängig von der Mikroumgebung in der pro-
tumorigenen Phase. Während ein apoptotisches Milieu die Entstehung von HCC 
fördert, fördert ein nekroptotisches Milieu die Entstehung von ICC. Dies ist 
unabhängig von der Komposition der infiltrierenden Immunzellen, jedoch mit einer 
spezifischen Zytokinsignatur assoziiert. Diese kann durch Inhibition von Nekrose auf 
chemischem oder genetischem Wege revertiert werden, was einen Wechsel von ICC 
zu HCC zur Folge hat.  
Epigenetik- und Transkriptomanalysen von Zelllinien, welche aus murinen HCC- und 
ICC-Tumoren isoliert wurden konnten zeigen, dass es Tumortyp-spezifische 
Signaturen gibt, obwohl beide Tumorarten initial durch Transfektionen von 
Hepatozyten mit denselben Onkogenen induziert wurden. Integrative Analysen von 
Epigenom- und Transkriptomdatensätzen zeigten, dass die Transkriptionsfaktoren 
Tbx3 und Prdm5 zwischen HCC und ICC epigenetisch differentiell reguliert sind, was 
auch in einer großen Kohorte humaner Proben validiert werden konnte. Funktionelle 
Experimente zeigten, dass das Zusammenspiel von Tbx3 und Prdm5 die 
Tumorentwicklung vom HCC zum ICC ändern kann. Analysen von Downstream-
Targets zeigten, dass beide Transkriptionsfaktoren unterschiedliche Signalwege 
kontrollieren, was die Wichtigkeit der Wechselwirkung beider Faktoren für die 
Bestimmung der Entwicklung von primären Lebertumoren zeigt. 
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1. Introduction 
1.1. Primary liver cancer 
1.1.1. Etiology and risk factors 
With more than 1 million newly diagnosed patients per year primary liver cancer 
(PLC) represents a major health problem1. The incidence rates were increasing by 
21% from 2006 to 2016 especially in western countries. It is the fourth leading cause 
of neoplasia-related death with more than 800,000 people dying each year which is 
mainly based on the lack of reliable biomarkers, efficient therapies and late 
diagnosis2-4.  
The two most prominent subtypes of PLC are hepatocellular carcinoma (HCC) 
accounting for 80% of all PLC and the cholangiocarcinoma (CCA) counting for 10-
20%. While the ratio between male and female is 3-5:1 for HCC it is less gender 
dependent for CCA with a ratio of 1.2-1.5:15. HCC account for more than 700,000 
deaths per year worldwide with still increasing incidence rates from 1.4/100,000 
cases per year between 1976 and 1980 to 6.2/100,000 cases per year in 20116, 7. 
HCC preferably develops in patients with chronic liver diseases like cirrhosis, non-
alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH) or 
alcoholic steatohepatitis (ASH)8, 9. Chronic liver damage and inflammation due to 
obesity, metabolic disorders, alcohol abuse or infection with hepatitis B virus (HBV) 
or hepatitis C virus (HCV) are predispositions for these diseases. However, recent 
anti-HCV therapies lead to high success rates in eradicating HCV10.  
Classification of CCA is based on the localization within biliary tree. Extrahepatic 
tumors arising at the distal end are classified as distal CCA (dCCA) and extrahepatic 
tumors at the bifurcation of the common bile duct as perihilar CAA (pCCA) while 
intrahepatic tumors are classified as iCCA or ICC. However, these classifications are 
sometimes difficult to diagnose in patients which lead to misclassification within these 
tumor entities. As a consequence mortality rates are quite different between most 
reported studies. Some studies reported decreasing rates within the last years while 
other reported an increase up to 15-fold11. While in Eastern countries infections with 
liver flukes like Opisthorchis viverrini or Clonorchis sinensis are predominantly 
favoring ICC development in Western countries risk factors are more variable. It has 
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been shown that infection with HBV or HCV, or cirrhosis also increases the risk for 
ICC development as well as alcohol abuse and fatty liver diseases12-15. Interestingly, 
as described earlier these are also risk factors for HCC. Collectively, ICC as well as 
HCC both develop in a milieu of chronic liver damage and inflammation16. 
1.1.2. Diagnosis and treatment options 
A major issue of liver cancer therapy is the diagnosis due to the lack of early 
symptoms. Most patients are diagnosed when they already have advanced HCC or 
ICC limiting their treatment options2. The use of biomarkers is generally a good tool 
for early detection of diseases. However, until now alpha-fetoprotein (AFP) is the only 
widely used biomarker for HCC. The problem is the lack of sensitivity and that this 
marker usually correlates with advanced stages reducing their predictive use. So, 
additional methods as imaging or biopsy are still necessary17. The only curative 
therapy for HCC is surgical removal of the tumors or total liver transplantation. 
However, due to late diagnosis and limited availability of donor organs only a small 
number of patients are eligible for surgical treatment18, 19.  
The only approved drug for first line HCC treatment is the multi-kinase inhibitor 
sorafenib which, however, can only give a survival benefit of 2.8 months20. Recently, 
regorafenib and cabozantinib were approved as a second line therapy for patients 
who formerly received sorafenib treatment which could further increase the survival 
for 2.8 and 2.2 months, respectively21, 22. Furthermore, due to good results from a 
phaseI/II study the checkpoint-blocking antibody nivolumab was also approved as 
second-line therapy after sorafenib treatment23.  
Similar to HCC diagnosis of ICC often occurs at late stages. The mostly used 
biomarker are carbohydrate antigen 19-9 (CA 19-9) and carcinoembryonic antigen 
(CEA), however, they are not sufficient for a clear diagnosis and histopathological 
analysis of a biopsy is still necessary in clinical routine24. Surgical resection is still the 
only curative option although the 5-year survival rate after resection is low (32%) due 
to high recurrence rates of the tumors25-27. A systemic therapy treatment with 
gemcitabine and cisplatin is the standard drug treatment, however, on average it can 
only prolong the survival by 3.6 months compared to gemcitabine alone28. By now, 
there is no targeted therapy which is approved for ICC. 
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1.1.3. Molecular and cellular pathogenesis 
Both HCC and ICC develop in an environment of chronic damage and inflammation. 
Liver-resident immune cells as stellate or Kupffer cells mainly contribute to these 
circumstances via releasing pro-inflammatory cytokines or directly interacting with 
liver cells29-32. Although the liver has a remarkable regenerative capacity it can be 
exhausted under long-term damage. In the context of chronically damaged, cirrhotic 
livers dysplastic nodules develop, which show genetic aberrations8, 33. Similar to their 
risk factors HCC and ICC also share many of these genetic aberrations. Comparative 
analyses of different TCGA datasets showed that mutations in Tumor protein p53 
(TP53, 25% in HCC, 21% in ICC), AT-rich interactive domain-containing protein 1A 
(ARID1A, 12% in HCC, 14% in ICC), myeloid/lymphoid or mixed-lineage leukemia 
(MLL, 5% in HCC, 5% in ICC) and synaptic nuclear envelope protein 1 (SYNE1, 5% 
in HCC, 3% in ICC) occur frequently in both tumor entities34-37. Summarizing the 
shared mutations into signaling pathways showed that cell cycle control and 
epigenetic regulation are key factors of HCC as well as ICC development5. 
However, each of the tumor types also harbors unique alterations. HCC for example 
often has mutations in Telomerase reverse transcriptase (TERT, 59-68%), catenin 
beta-1 (CTNNB1, 16-62.5%) or Janus kinase 1 (JAK1, 45.5%). Mutations enhancing 
telomerase activity were shown to be an early event to enhance regenerative 
capacity, while CTNNB1 mutations lead to activation of pro-survival and proliferative 
Wnt/β-catenin pathway38. 
On the other hand ICC show mutations in Kirsten rat sarcoma viral oncogene 
homolog (KRAS, 54%), Isocitrate dehydrogenase (IDH1/2, 8-16%), BRCA1 
associated protein-1 (BAP1, 20%) or fibroblast growth factor receptor 2 (FGFR2-
fusion, 14-45%) (Fig. 1)5, 39. Especially KRAS mutations and FGFR2-fusion affect 
uncontrolled proliferation of these tumors. Importantly, mutational landscape of ICC 
strongly depends on liver-fluke infection status40. 
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Figure 1 Genetic alterations in HCC and ICC Shown are the most prominent alterations and pathways in HCC 
and ICC development (adapted from
5
). 
Studies to identify the cell of origin for HCC, ICC or mixed HCC/ICC tumors are 
conducted since many years, however, the results are still diverse. Historically it has 
been suggested that HCC derives from hepatocytes and ICC derive from 
cholangiocytes. However, there is increasing evidence that lineage commitment in 
PLC development is much more complex and plastic than that41, 42.  
Cholangiocytes were thought to be the cells of origin for ICC due to their similarities 
in morphology and histopathology. Evidences for this theory came from a lineage 
tracing mouse model where cholangiocyte specific deletion of Trp53 together with 
thioacetamide (TAA) induced liver damage induced ICC development. However, this 
study also showed that hepatocytes express cholangiocarcinoma-specific Notch after 
liver injury suggesting that cholangiocytes are not the only cells of origin43. 
Liver progenitor cells (LPC) are able to differentiate into hepatocytes or 
cholangiocytes upon liver damage to maintain the regenerative capacity of the liver. It 
has been suggested by several studies that LPC can also develop into both HCC and 
ICC44, 45. Further, it has been demonstrated that suppression of p53 in LPC restricts 
stem cell capacity and can lead to HCC as well to ICC development46. Another study 
showed that IDH mutations in LPC lead to suppression of hepatocyte nuclear factor 4 
alpha (HNF4alpha) favoring ICC initiation33.  
Interestingly, several recent studies further proved that hepatocytes can also develop 
into both HCC and ICC. These studies demonstrated that activation of the Hippo-
YAP pathway or PI3kinase and MEK-ERK pathway in hepatocytes lead to HCC 
development47, 48. In contrast hepatocyte-specific forced activation of Notch or Notch 
and PI3kinase pathway induces ICC development49-51. This was accompanied with a 
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reprogramming of the hepatocytes into a biliary-type cell (Fig.2). Interestingly, it has 
further been shown that such a reprogramming event also occurs upon liver injury52.  
Figure 2 Cells of origin in PLC Overview of different putative cells of origin for HCC, mixed HCC/ICC and ICC 
and the main oncogenic drivers. (adapted from
5
). 
Independent of the cell of origin the morphology of HCC and ICC are quite different. 
HCC usually growth in a dense or trabecular pattern without stromal parts. 
Immunohistopathological markers used for classification and diagnosis are 
gluthamine-synthetase (GS) or glypican 3 (GP3)53. In contrast, ICC growth occurs in 
glandular, bile-duct-like, structures with up to 60% of stroma tissue showing high 
similarities to pancreatic ductal adenocarcinoma (PDAC). Typically used markers for 
PDAC as well as ICC are cytokeratins 7 and 19 (K7/K19)3, 54.  
1.2. Cell death in chronic liver disease 
Hepatocyte cell death frequently occurs in chronically damaged livers. There are two 
major forms of cell death the unregulated and the regulated one. Unregulated cell 
death, also described as necrosis, occurs under extreme conditions like physical, 
chemical or heat induced stress which directly disrupts cell integrity. Regulated cell 
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death on the other hand has a huge variety of different forms which have specific 
trigger events and downstream pathways55.  
The most prominent one is apoptosis which itself can be separated into the intrinsic 
and extrinsic from. Intrinsic apoptosis occurs under harmful conditions for the cell, for 
example starvation, high levels of reactive oxygen species (ROS), DNA damage or 
replicative stress56, 57. These conditions can alter the balance of pro- and anti-
apoptotic members of the B-cell lymphoma 2 (BCL2) family like BAX, BAK or BOK 
and BCL-2 or BCL-XL, respectively58-61. The pro-apoptotic members can then induce 
permeabilization of the outer mitochondrial membrane (MOMP) resulting in a release 
of cytochrome-c and similar factors finally activating caspases as CASP9, CASP3 or 
CASP762-66. These caspases then execute the final steps of the apoptotic cascade 
like DNA degradation and disruption of the membrane into apoptotic bodies67, 68.  
Extrinsic apoptosis can be triggered via cell death receptors as CD95 (also known as 
Fas) or members of the tumor necrosis factor receptor superfamily (TNFRSF). 
Activation of these receptors leads to induction of extensive downstream signaling 
cascade finally again activating same caspases as in the intrinsic pathway69.  
Another form of controlled cell death is necroptosis, also called controlled necrosis. 
Necroptosis can be triggered via activation of several receptors like TNFR1/2, Fas, 
toll-like-receptor (TLR) 3 or 4 or cell intrinsically via DNA sensors like DAI70-72. These 
receptors can then activate receptor interacting serin/threonine protein kinase (RIPK) 
3 in a RIPK1 dependent or independent manner. However, this can only happen if 
caspase-8 is inactive as it is able to inhibit this mechanism55, 69. Activated RIPK3 then 
phosphorylates mixed-lineage kinase domain like pseudokinase (MLKL), 
subsequently forming multimeric pores integrating into the plasma membranes73, 74. 
This disruption of membrane integrity leads to release of high amount of damage-
associated molecular patterns (DAMPs) as adenosintriphosphate (ATP), high mobility 
group box protein (HMGB) 1, interleukin 33 (Il-33) or cellular DNA and RNA. Due to 
this extensive release necroptosis is usually followed by inflammatory events (Fig. 
3)69, 75, 76.  
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Figure 3 Cell death mechanisms Overview of the three most important cell death mechanisms and their 




Apart from these two forms of controlled cell death there are many other forms of cell 
death. Especially in the last years more and more were identified or newly defined, 
e.g. pyroptosis which is induced by pathogen infection, anoikis which occurs when 
cells loose integrin-dependent anchorage or autophagy-related cell death55, 78, 79. 
Most of these cell death mechanisms share the core machinery, however, induction 
and execution differ between them. 
Hepatocyte cell death is one of the most important markers for chronic liver damage 
or disease as NASH, NAFLD or cirrhosis (Fig.4)69. Necrosis induction in the liver is 
well studied in mouse models, nonetheless data on necrosis in livers of human 
patients are limited as necrosis is difficult to identify. It has been shown that acute 
intake of alcohol or drugs (e.g. acetaminophen (APAP)) or ischemia-reperfusion 
injury (IRI) can induce high amounts of necrosis in the liver80.  
Apoptosis is much more studied in the induction of liver diseases. Extrinsic apoptosis 
can be induced via HBV or HCV infection, activation of cell death receptors by pro-
inflammatory immune cells or Fas activation by bile-acids in cholestatic livers. These 
conditions can lead to decreased cellular functions which then might induce further 
intrinsic apoptosis activation due to nutrient starvation or accumulation of 
endosplamic-reticulum (ER) or genotoxic stress69, 81-83. Importantly, hepatocytes are 
the most prominent but not the only cells undergoing cell death in the liver. It has 
been shown that also cholangiocytes or liver-resident immune cells undergo cell 
death in chronically damaged livers84, 85.  
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Figure 4 Cell death in liver cancer Cartoon of contributions from different cell death mechanisms to chronic liver 
disease and cancer (adapted from
86
). 
The high amount of cell death contributes to liver disease and carcinogenesis in 
different ways. Especially necrotic or necroptotic damage leads to infiltration of 
immune cells via DAMP release. These immune cells then release cytokines 
enhancing hepatic stellate cell (HSC)-dependent fibrogenesis and hepatocyte or 
cholangiocyte proliferation. Uncontrolled levels of fibrosis induction and pro-
proliferative pathways in hepatocytes, cholangiocytes or hepatic stem cells then lead 
to induction of PLC69, 75, 86, 87. There are several studies directly linking apoptosis to 
HCC development, however, for necroptosis this is much more controversial69. It has 
been reported that necroptosis is associated with ethanol-induced liver damage, 
cholestasis, NASH or fibrosis highlighting its importance in liver disease88-90. 
However, there is currently no evidence that necroptosis favors either HCC or ICC 
development. 
1.3. Role of epigenetic in cellular fate and cancer 
Epigenetic regulation is a fast and flexible mechanism to regulate gene expression 
upon external or internal stimuli but also to inherit information over several 
generations. In contrast to genetic alterations epigenetic regulation is reversible as 
no changes in the nucleotide sequences occur91, 92. The most important role of 
epigenetics lies in regulating the development of an organism. Usually a pluripotent 
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stem cell differentiates into a huge variety of other cell type via epigenetic regulation 
of its gene expression93.  
There are many different mechanisms of epigenetic regulation. One of them is the 
direct modification of the DNA at so called CpG-islands via DNA methyltransferases 
DNMT1, DNMT3A or DNMT3B. These enzymes methylate C5 position of cytosines 
located 5’ to guanosines. These CpG-islands are mainly found in the vicinity of 
promotor regions enabling them to affect the transcription of genes via regulating the 
binding of factors of the transcription machinery94, 95.  
Another important epigenetic characteristic is the chromatin appearance which is 
mostly affected by interaction with histones. Histones are proteins usually occurring 
in an octamer form bound to DNA (147 bp per octamer) due to their positive 
charge96. This charge can be regulated via modifying acetylation sites by histone 
acetyltransferases (HATs) or histone deacetylases (HDACs). Depending on the 
acetylation status of histones the chromatin occurs in an open and active form or in a 
condensed inactive form. However, histones can also be modified via methylation, 
ubiquitination or phosphorylation (Fig. 5). This can be either activating or inactivating 
depending on the site of modification within the histones and the target structure for 
these modifications97-99.  
 
Figure 5 Epigenetic regulations in the cell Summary of the main regulations for epigenetic changes influencing 
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One such target structure is the chromatin remodeling complex switch/sucrose non-
fermentable (SWI/SNF) which is able to alter histone and chromatin structure and 
interaction thereby affecting gene transcription96. The SWI/SNF complex consists of 
several subunits and co-regulators which are frequently mutated in HCC and ICC5. 
It has been shown that lineage commitment through epigenetic regulations in 
hematopoietic cells is directly affected by environmental conditions. For example 
non-specialized macrophages gain different histone modifications after residing in 
different organs. Especially methylation of H3K4 in promotor and enhancer regions of 
pioneer transcription factors alter gene expression and pathways resulting in tissue-
specific differentiation (Fig. 6)101. Other studies on macrophage specialization 
showed that transforming growth factor beta (TGFβ)/SMAD pathway or retinoic acid 
(RA)/GATA6 pathway activation via environmental signals influences lineage 
commitment102-104. 
 
Figure 6 Environment-dependent fate decisions of macrophages Parental macrophages change their 




It has been shown many years ago that epigenetics also plays an important role in 
cancer via activation of oncogenes or suppression of tumor suppressors which has 
also been reported for HCC and ICC105-107. Studies identified promotor 
hypermethylation for cyclin-dependent kinase Inhibitor 2A (CDKN2A, 62.5% HCC, 
50% ICC), Ras association domain family member 1 (RASSF1A, 60% HCC, 65% 
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ICC) or cadherin 1 (Cdh1, 33% HCC, 43% ICC) pinpointing the importance as well as 
similarity of epigenetic dysregulation in both cancer types108-111. As mentioned earlier, 
the chromatin remodeling complex SWI/SNF and its pathway is highly deregulated in 
both tumor entities. Especially mutations in ARID1A which is a member of the 
SWI/SNF complex frequently occur in both tumor types. Further, mutations in the 
MLL family representing important histone methyltransferases are also increased in 
both tumor entities5. Interestingly, IDH which is frequently mutated in ICC leads to 
epigenetic silencing of HNF4alpha in hepatoblasts inhibiting hepatocyte 
differentiation and favoring ICC development.33 
1.4. Aim of the study 
Until now it is unknown which factors or circumstances favor the development of 
either HCC or ICC in chronically damaged liver of the same etiology.  
The first aim of this study was to identify the cell of origin of HCC and ICC induced by 
the same oncogenes via hydrodynamic tail vein injection (HDTV) or in vivo liver 
electroporation (Epo), respectively. Then, we set out to analyze if somatic mutations 
might account for differences in tumor development. We further aimed to perform 
functional analyses if the conditions followed by HDTV or Epo might account for 
lineage commitment and to subsequently characterize these conditions. This 
characterization was focused on the inflammatory milieu as well as cell death 
occurrence in the liver. We focused on examining putative connections between the 
microenvironment and lineage commitment utilizing functional experiments.  
Finally, the goal was to characterize a potential role of epigenetic regulation for HCC 
vs. ICC development and aimed to functionally probe epigenetically regulated 
candidate genes.  
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2. Material and Methods 
2.1. Material 
2.1.1. Chemicals  
If not mentioned elsewhere, chemicals and solutions used in this study were 
purchased from the following companies: AppliChem, Biosciences, Carl Roth, 
Fermentas, Fluka, GE Healthcare, Invitrogen, Life Technologies, Merck, Millipore, 
Promega, Peqlab, Serva and Sigma Aldrich. 
2.1.2. Enzymes 
All restriction enzymes, DNAseI, calf intestinal alkaline phosphatase (CIP) or 
recombinant shrimp alkaline phosphatase (rSAP) and T4-DNA-ligase were 
purchased from NEB, dispase and collagenase were purchased from Roche or 
Serva, Platinum Pfx Polymerase was purchased from Invitrogen and proteinase K 
was purchased from Sigma Aldrich. 
2.1.3. Kits 
Table 1 Kits used in this study 
Kit Company 
Mouse Gene 2.0 ST Array Affymetrix 
GeneChip WT PLUS Reagent Kit Affymetrix 
GeneChip Hybridization, Wash, and Stain Kit Affymetrix 
SureSelect Mouse AllExon XT Target Enrichment Kit Agilent 
TaqMan Reverse Transcriptase Kit Applied Biosystems 
PCR SYBR Green MasterMix Applied Biosystems 
DC-Protein Assay Biorad 
SimpleChIP kit Cell Signaling 
Q5 Site-Directed Mutagenesis Kit NEB 
KAPA Hyper Library Prep Kit PEQLAB 
Plasmid Maxi Kit Qiagen 
Qiaquick Gel Extraction Kit Qiagen 
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RNeasy Mini Kit Qiagen 
QIAamp MicroKit Qiagen 
QIAGEN MinElute kit Qiagen 
QIAGEN PCR Cleanup kit Qiagen 
In Situ Cell Death Detection Kit Fluorescein Roche 
In Situ Cell Death Detection Kit TMR-Red Roche 
Accel-NGS 2S Plus DNA Library Kit Swift Bioscience 
PrimeScript RT Master Mix Takara Clontech 
SYBR Premix Ex Taq (Tli RNase H Plus) Takara Clontech 
Arcturus HistoGene LCM Frozen Section Staining Kit Thermo Scientific 
Qubit® dsDNA HS Assay Kit Thermo Scientific 
DAB solution Zytomed 
2.1.4. Buffers and solutions 
Table 2 buffers and solutions used in this study 
buffer/ solution composition 
ACK-buffer 150 mM NH4Cl, 10 mM KHCO3, and 0.1 mM EDTA 
Anesthesia 
2 ml Ketamin (50 mg/ml), 500 µl Xylazin (20 mg/ml), 
ad 10 ml 0.9% NaCl 
ATAC-lysis-buffer 
10 mM Tris-HCl, pH 7.4, 10 mM NaCl, 3 mM MgCl2, 
0.1% IGEPAL CA-630 
Cell-medium 
500 ml DMEM, 5 ml Pen/Strep, 5 ml 100X MEM 
NEAA, 5ml 100X sodiumpyruvate, 50ml FCS 
Digestion medium 
1 ml HBS (10x), 10,000 units dispase, 1 units 
collagenase, ad 10 ml DMEM  
gDNA extraction buffer  
20 mM Tris-HCl (pH 8.0), 100 mM EDTA, 100 mM 
NaCl 1 % SDS, 0,5 mg/ml Proteinase K  
HBS (10x)  
7.5 mM Na2HPO4 (pH 7.0), 1.4 M NaCl, 250 mM 
HEPES, 60 mM Dextrose, 50 mM KCl  
Laemmli- buffer (5x)  
150 mM Tris-HCl (pH 6.8), 6 % SDS, 15 mM DTT, 30 
% glycerol, 0.25 % bromphenolblue  
LB-medium 1 l H20, 20 g LB-powder (Roth), 50 mg/l ampicillin 
NP40 lysis buffer  
50 mM TrisHCl (pH 7.5), 15 0mM NaCl, 0,5 % NP-40, 
1x Complete mini® (Roche)  
PBS (10x)  100 mM Na2HPO4*2H2O, 20 mM KH2PO4, 1,37 M 
22  Material and Methods 
   
 
NaCl, 27 mM KCl (pH 7,4)  
PBST  0.1 % Tween 20 in PBS  
Permeabilization-buffer  
5 % NGS, 0.2 % Triton X-100, 0.1 % Tween 20 in 
PBS  
PFA in PBS  4 % PFA in PBS (pH 7.4)  
SDS-running buffer (10x)  250 mM Tris Base, 1.92 M Glycine, 1 % SDS  
Sodium citrate buffer  10 mM C6H5Na3O7 (pH 6.0)  
TAE (50x)  
2 M Tris Base (pH 8.5), 1 M glacial acetic acid, 50 
mM EDTA  
TBS (10x)  500 mM Tris-HCl, (pH 7.4), 1500 mM NaCl  
TBST  0.1 % Tween 20 in TBS  
Transfer buffer  
48 mM Tris-HCl (pH 8.3), 39 mM Glycine, 20 % 
Methanol, 0,037 % SDS  
2.1.5. Antibodies 
Table 3 antibodies used in this study 
Primary antibodies: 
clone antigen species company conjugation application 
A-20 Tbx3 goat Santa Cruz 
 
ChIP 
MABE972 Prdm5 ms Merck 
 
ChIP 
30-F11 CD45 rat BD BV421 FC 
HK1.4  Ly6C rat eBioscience Alexa Fluor 488 FC 
M1/70  CD11b rat eBioscience PE FC 
53-6.7  CD8a rat eBioscience PE FC 
17A2  CD3 rat eBioscience eFluor 660 FC 
RB6-8C5  Ly-6G (Gr-1)  rat eBioscience PE-Cyanine7 FC 
RM4-5  CD4 rat eBioscience APC FC 
BM8  F4/80 rat BioLegend APC FC/IF 
TROMA-III K19 rat DSHB 
 
IHC/IF 
GEN135-35-9 pRIPK3 rb Genentech 
 
IHC 
1G6.1.4 RIPK3 rat Genentech 
 
IHC 
C-19 HNF4α  goat Santa Cruz 
 
IHC 
1A8 Ly6G rat BD 
 
IHC 
M5/114.15.2 MHCII  rat Novus Biologicals 
 
IHC 
Material and Methods  23 
   
RA3-6B2 B220  rat BD 
 
IHC 
SP7 CD3 rb Zytomed 
 
IHC 
A2547 αSMA ms Sigma Aldrich 
 
IHC 
5A1E cl. caspase 3 rb Cell Signaling 
 
WB 
EPR9515(2) pMLKL (S345) rb abcam 
 
WB 
hVIN-1 vinculin ms Sigma Aldrich 
 
WB 
11H10 tubulin rb Cell Signaling 
 
WB 
AC-74 beta-actin ms Sigma Aldrich 
 
WB 
orb32399 MLKL rb Biorbyt 
 
WB 
   
 Secondary antibodies: 
clone antigen species company conjugation application 
 











Thermo Scientific biotin 
     
 
2.1.6. Oligonucleotides 
Table 4 oligonucleotides used in this study 
qPCR Primer sequences 
Gene Sequence 
ß-actin fw CCACCGATCCACACAGAGTA 
ß-actin rev GGCTCCTAGCACCATGAAGA 
Tbx3 fw CCACCTCCAACAACACGTTCT 
Tbx3 rev TAAGGAAACAGGCTCCCGAA 
Prdm5 fw TCAGAAAAGCGGCCTTATAACTG 
Prdm5 rev CCACTTGATCGAGCCTCTTGAAG 
Rip3 fw GCGGCCGCGGatggttaatcttcgtaatgag 
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Cloning of Fam72aMUT 
Fam72a for  ggcgcgccGCCGCC ATGTCTACCAACAACTGTACTTTCAA  
Fam72a rev  GGGACCGGTTCATCGAATATACTCTTCTGCTGA 
Fam72aMUT for CCACGTAATTTTTCCATGTAGTTC 
Fam72aMUT rev TAGCCTACAATGTTCCCAC 
Cloning of Prdm5 
AscI Prdm5 for GGCGCGCCGCCGCCatgctgggcatgtacgt 
NheI Prdm5 rev  GGGGCTAGCTTAGCTGTCAGCTACCCCA 
Cloning of Tbx3 
AscI Tbx3 for  ggcgcgccGCCGCCatgagcctctccatgagag 
AgeI Tbx3 rev in PolyI:  GGGACCGGTTTAAGGGGACCCGCT 
2.1.7. Plasmids 
The sleeping beauty plasmids (SB13) were provided by David Largaespada. 
Transposon plasmids encoding c-Myc and Nras (pCaMIN) or c-Myc and AKT-1 
(pCaMIA) were generated by Florian Heinzmann and Anja Hohmeyer, respectively, in 
our lab. Transposons encoding Fam72a and mutated Fam72a (259G>T), Tbx3 (Tbx3 
OE) and Prdm5 (Prdm5 OE) were also cloned by Florian Heinzmann in our lab. The 
retroviral vector including TRE3G promotor, EGFP sequence, mirE shRNA 
backbone, PGK promotor, puromycin resistance cassette, IRES and an rtTA3 coding 
sequence (RT3GEPIR) was provided by Johannes Zuber. The plasmid encoding 
Cas9n and an sgRNA targeting p19 (CCsgp19) based on the px330 plasmid was 
kindly provided by Wen Xue. The shRNA sequences targeting Tbx3 or Prdm5 were 
subcloned into RT3GEPIR or pCAMIN by Florian Heinzmann and Marco Seehawer, 
respectively. 
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2.1.8. Bacteria 
For transfections and overnight cultures Subcloning efficiency DH5α Escherichia coli 
cells from Invitrogen were used. 
2.1.9. Cell lines 
For virus production the genetically modified human embryonic kidney cell line 
(HEK293T) Phoenix-AMPHO (ATCC:CRL-3213) was used. HCC or ICC cell lines 
used in this study were isolated from tumors of p19-/- mice after pCaMIN/SB13 
delivery via hydrodynamic tail vein injection or in vivo liver electroporation. From each 
cell line single cell lines were generated via serial dilutions. 
2.1.10. Mouse strains 
Wildtyp mice (C57BL/6, CB17, C3H/HeN) and immunodeficient SCID/beige (CB17) 
as well as Rag2-/- (C57BL/6) knockout mice were purchased from Charles River or 
the Jackson Laboratory. p19-/- (C57BL/6) mice have been generated by Charles 
Sherr and were obtained from Scott W. Lowe. AlbCre x MLKLfl/fl (C57BL/6) were 
provided by Mihael Vucur and Tom Luedde. 5xTLR KO mice (C57BL/6) were kindly 
provided by Thorsten Buch. TLR 2/4 KO (C3H/HeN) mice were obtained from 
Alexander Weber. AlbCre mice were purchased from The Jackson Laboratory and 
crossed with the ROSAmT/mG mice (generated by Liqun Luo, obtained from Johannes 
Zuber) and were intercrossed with p19-/- mice by Lisa Hoenicke. 
2.2. In vivo experiments 
2.2.1. Mouse husbandry 
All experimental mouse studies have been approved by the responsible local 
authority (Regierungspräsidium Tübingen), Baden-Württemberg. Mice were housed 
in type II long cages with food and water ad libitum under specific pathogen-free 
conditions according to guidelines of the University of Tübingen. 
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2.2.2. Hydrodynamic tail vein injection (HDTV) 
For HDTV 25 µg transposon plasmid and 5 µg SB13 transposase plasmid were 
mixed and filled up with 0.9% sodium chloride solution to 10% of the mouse 
bodyweight. For experiments in wt mice, additional 10 µg of the Crispr/Cas9-sgp19 
plasmid was added. Mice were fixed in a restrainer and the tail was warmed with 
water. Then the solution was injected into the tail vein of the mouse with a syringe 
and a 25G needle within 5 to 10 seconds.  
2.2.3. In vivo liver electroporation (Epo) 
Prior to Epo 25 µg transposon plasmid was mixed with 5 µg SB13 transposase 
plasmid and filled up with TE buffer to 50 µl. For experiments in wt mice 10 µg of 
Crispr/Cas9-sgp19 plasmid was added. Mice were anaesthetized with a mix of 
ketamine (100 mg/kg bodyweight) and xylazin (10 mg/kg bodyweight) and a small 
laparotomy below the thorax was conducted. The left lateral liver lobe was exposed 
and the plasmid solution was injected with a 30G needle into the liver capsule. The 
injected lobe was placed between tweezer of an electrode (CUY650P5, 5 mm 
diameter) and 2 electric pulses (75 V, 75 ms, 500 ms interval) were applied with a 
Square Wave Electroporator (CUY21SC, Nepa Gene, Japan). The liver lobe was 
placed back and the mouse was closed with resorbable suture material and individual 
stitches.  
2.2.4. Bile duct ligation 
Mice were anaesthetized and a laparotomy was performed as described earlier. The 
common bile duct was exposed with micro forceps and ligated with non-resorbable 
suture material. The liver was placed back and the mouse was closed with 
resorbable suture material and single stitches. 
2.2.5. Liver perfusion 
Mice were anaesthetized and liver perfusion medium (Invitrogen) was injected 
through the vena cava for 15 min. Afterwards it was exchanged with collagenase 
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(Serva) and Ca2+ supplemented medium for 15 min. Liver was harvested and 
hepatocytes were detached via gently shaking and purified via Percoll centrifugation. 
2.2.6. Subcutaneous tumor cell injection 
Cells were detached with 0.05% trypsin/EDTA working solution and washed 2 times 
with PBS and separated through a 100 µm mesh. Then they were counted using a 
counting chamber and diluted in sterile PBS to a concentration of 2x106/100 µl. Mice 
were anaesthetized as described before and cells were injected into the left and right 
flank with a 30G needle. 
2.3. Histological methods 
2.3.1. Hematoxylin/eosin (H&E) and immunohistochemistry staining (IHC)  
Collected tissue samples were fixed with 4% paraformaldehyde (PFA) o/n and 
embedded in paraffin. They were cut with a microtome into 4 µm thick slices and 
dried at 65°C o/n. They were hydrated via incubation in xylol, xylol/ ethanol 
(50%/50%), 90% ethanol, 70% ethanol, 50% ethanol and water for 3 min each. For 
H&E staining samples were incubated 8 min in hematoxylin (Gil II), rinsed with water 
and developed under running tap water for 10 min. Afterwards they were incubated in 
eosin Y solution for 3 minutes, washed with water and dehydrated via incubation in 
90% ethanol, xylol/ ethanol (50%/50%) and xylol for 5 min each. Finally, samples 
were mounted with NeoMount and covered with a glass slide. For IHC antigen 
retrieval was performed after the hydration steps in boiling sodium citrate buffer (10 
mM, pH 6.0, 0.5% Tween-20) in a rice cooker for 15 min. Then endogenous oxidases 
were saturated using 3% H2O2 for 5 min. The samples were circled with a PAP pen 
and blocked with blocking solution (Zytomed) or 5% BSA for 10 min and incubated 
with the primary antibody o/n at 4°C. Slides were washed with TBST and incubated 
with the secondary antibody for 1h at RT. After another washing step biotin-HRP 
solution (1:300, Dako) was added for 15 min and samples were washed again. DAB 
developing solution (Zytomed) was added until specific staining was visible under the 
microscope. Developing was then stopped via adding water and samples were 
counterstained with hematoxylin only and mounted as described before. 
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2.3.2. Native fluorescence staining 
To detect native fluorescent signal in mouse livers samples were harvested and fixed 
with 4% PFA for 4 h at 4°C. Samples were then dehydrated in 30% sucrose solution 
at 4°C o/n and embedded in TissueTek (Sakura) at -80°C. Samples were cut with a 
cryotstat at -20°C into 6 µm slices and mounted with VECTASHIELD HardSet 
mounting medium with DAPI (Vector Labs). 
2.3.3. Immunofluorescence staining (IF) on paraffin slides 
Samples from ROSAmT/mG x AlbCre x p19-/- mice were fixed with 4%PFA and 
embedded in paraffin which quenched native tomato signal while native GFP signal 
was still visible. Samples were then cut and processed as described before until 
incubation with the primary antibody. Then AlexaFluor 594 coupled secondary 
antibody was added for 1 h at RT and slide was washed with PBST. Finally slides 
were mounted with VECTASHIELD HardSet mounting medium with DAPI (Vector 
Labs). 
2.3.1. Immunofluorescence staining (IF) on cells 
Cells were plated on Tissue Culture Chambers (Sarstedt) and incubated o/n. Then 
cells were fixed with 4% PFA at 4°C for 10 min, washed with PBST and 
permeabilized with permeabilization buffer (2.1 Materials) for 60 min at RT on a 
shaker. After three washing steps with PBST primary antibody was incubated in 1% 
NGS in PBST for 60 min at RT on a shaker. Samples were washed three times with 
PBST and fluorescent dye-labelled secondary antibody in 1% NGS in PBST was 
added for 60 min at RT under shaking. Samples were again washed three times with 
PBST and finally mounted with VECTASHIELD HardSet mounting medium with DAPI 
(Vector Labs). 
2.3.2. Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) 
TUNEL staining on cryosections has been performed with the CellDeath Detection Kit 
Fluorescein (Roche) according to the manufacturer’s protocol. For staining of 
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ROSAmT/mG x AlbCre x p19-/- mouse samples CellDeath Detection Kit TMR Red 
(Roche) was used. For quenching native tomato but retaining native GFP signal 
protocol was adjusted as following: Fixation step was reduced to 5 min, 
permeabilization step was reduced to 2 min and incubation duration was reduced to 
15 min. 
2.3.3. Laser capture microdissection (LCM) 
For LCM procedure samples were directly embedded in TissueTek and frozen at -
80°C. They were cut with a cryostat at -20°C and stained with Arcturus HistoGene 
LCM Frozen Section Staining Kit to maintain DNA quality. LCM was then performed 
using a Zeiss PALM MicroBeam and PALMRobo Software. From each sample 
material from at least 10 sections was collected.  
2.4. Cell culture  
2.4.1. Standard cell culture 
Cells were maintained under sterile conditions in an incubator at 37°C and 7.5% CO2 
in modified DMEM media (2.1. Materials). When cells reached a confluency of 90% 
they were washed with PBS and detached using 0.05% trypsin/EDTA solution and 
10% were plated on a new dish. 
2.4.2. Establishing primary cell lines from tumors 
Tumors were harvested under sterile conditions and chopped with a scalpel into 
small pieces. 1 ml of digestion medium (2.1 Materials) was added and incubated at 
37°C for 30 min with constant shaking. Cell suspension was then filtered through a 
100 µm nylon mesh and cells were washed 2 times with PBS. Finally, cells were 
plated onto gelatin (1%) coated plates and incubated under normal conditions. 
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2.4.3. Production of retroviral particles 
Retroviral production was conducted using the Phoenix system. At 70% confluency 
Phoenix Ampho cells were treated with 25 µM chloroquine and incubated for 30 min 
at 37°C.Then, 25 µg of plasmid was mixed with 62.5 µl 2M CaCl2 and filled up with 
water to 500 µl. 500 µl of HBS buffer was placed into a FACS tube and the plasmid 
mix was slowly dropped into the HBS buffer while constantly bubbling air into the 
buffer. The mix was incubated for 10 min and slowly transferred to the cells. After 12 
h the media was refreshed. 24 h later the supernatant was harvested and filtered 
through a 0.45 µm filter.  
2.4.4. Stable transduction of cells 
Target cells were grown to 20% confluency and treated with 10 µg/ml polybrene for 
15 min and 100 µl of viral supernatant was added. After 24 h this procedure has been 
repeated. After additional 24 h successfully transduced cells were selected with 4-6 
µg/ml puromycin for 48 h. 
2.4.5. Flow cytometry analysis 
Liver samples were harvested and cut with a scalpel into small pieces. Then tissue 
was digested using collagenase (0.5mg/ml, Serva, NB 4G) in DMEM/HBS (1:1) for 30 
min at 37°C. Afterwards cold medium was added and cells were separated using a 
70 µm cell strainer and centrifuged at 800 rpm for 5 min. Erythrocytes were lysed 
with ACK buffer and cells were resuspended in 2%BSA/PBS and incubated with 
primary antibody for 30 min at 4°C. Then 1 µg/µl DAPI was added per sample and 
samples were measured with a FACSCanto (BD Biosciences). Data was analyzed 
with FlowJo (Tree Star).  
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2.5. Molecular biology techniques 
2.5.1. Plasmid preparation from bacterial cultures 
For high yield preparation 350 ml LB-medium including ampicillin was inoculated with 
the respective bacteria and incubated o/n at 37°C under constant shaking. Then 
MaxiPrep Kit from Qiagen has been used according to the protocol. 
For low yield preparation 5 ml LB-medium including ampicillin were inoculated with 
bacteria and incubated o/n at 37°C under constant shaking. Then, bacteria were 
pelleted via centrifugation with 2,000 rpm for 5 min and resuspended in 200 µl buffer 
P1. 200 µl buffer P2 was added and incubated for 5 min to lyse the cells and 
neutralization was done via adding 200 µl buffer P3. The solution was mixed and cell 
debris was pelleted via centrifuging at 13,300 rpm for 10 min. 500 µl supernatant was 
transferred into new reaction tubes and DNA was precipitated with 400 µl 
isopropanol. Then samples were centrifuged at 13,300 rpm for 15 min to pellet DNA 
and pellet was washed with 70% ethanol at 13,300 rpm for 5 min. The pellet was air-
dried and re-suspended in 30 µl water.   
2.5.2. Digestion of specific DNA fragments with restriction enzymes 
5 µg of genetic vectors or PCR products were digested with 0.5 µl of enzyme and the 
respective buffer (NEB) for 2 h at 37°C in a volume of 20 µl. If size separation was 
necessary the solution was run on an agarose gel (1.5%) at 120 V for 30 min and the 
correct band was cut out. Gel piece or digestion reaction was purified with QIAquick 
Gel Extraction Kit (Qiagen) according to manufacturer’s protocol. 
2.5.3. Dephosphorylation of DNA fragments 
Backbone was dephosphorylated with 1 µl recombinant shrimp alkaline phosphatase 
(NEB) with CutSmart buffer (NEB) in a total volume of 20 µl and column purified as 
described before. 
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2.5.4. Ligation of DNA fragments 
Ligation was performed using 0.5µl T4-ligase (NEB) and ligase buffer (NEB) over 
night with increasing temperature from 4°C to RT in a total volume of 10 µl and vector 
and insert according to the following formula: 𝑚(𝑖𝑛𝑠𝑒𝑟𝑡) =
𝑏𝑝(𝐼𝑛𝑠𝑒𝑟𝑡)
𝑏𝑝(𝑣𝑒𝑐𝑡𝑜𝑟)
∗ 6 ∗ 100 𝑛𝑔.  
2.5.5. Transformation of bacteria 
Subcloning Efficiency DH5α cells were mixed with 1/10 (v/v) plasmid solution and 
incubated on ice for 30 min. They were heat-shocked at 42°C for 20 sec and 
incubated again for 2 min on ice and finally plated on LB-agar plates with ampicillin 
and incubated o/n at 37°C. Next day, single colonies were picked and used to 
inoculate 5 ml LB-medium with ampicillin which was incubated o/n at 37°C under 
constant shaking. Then plasmids were isolated as described earlier and sent for 
Sanger sequencing to Seqlab/Microsynth to check for integrity. 
2.5.6. Polymerase chain reaction (PCR) 
Polymerase chain reaction (PCR) was conducted with Platinum Pfx Polymerase 
(Invitrogen) to amplify DNA fragments. Additional restriction sites were added with 
specifically designed primers (Table 4). PCR was conducted according to the 
following protocol (X= melting temperature -3°C): 
 
Table 5 PCR program for Pfx polymerase 
PCR program 
  94 °C 2 min 
  94 °C 15 sec 
}  X  °C 30 sec 25-35 cycles 
68 °C 1 min per kb 
 68 °C 5 min 
  4 °C ∞ 
  
2.5.7. Mutagenesis 
Mutagenesis for Fam72a (259G>T) mutations was done with Q5 Site-Directed-
Mutagenesis Kit (NEB) according to the manufacturers protocol. 
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2.5.8. Isolation of genomic DNA 
Samples were harvested and minced with a homogenizer into small pieces. They 
were digested using 300 µl gDNA extraction buffer at 56°C o/n under constant 
shaking. Digestion was inactivated at 95°C for 5 min and cell debris was precipitated 
by adding 50 µl of 5 M NaCl and again incubating for 5 min at 95°C. Samples were 
centrifuged at 13,300 rpm for 10 min and supernatant was transferred into new 
reaction tubes. Then 2/3 (v/v) of isopropanol was added and centrifuged at 13,000 
rpm and 4°C for 30 min to precipitate DNA. Pellet was washed with 500 µl 70% EtOH 
at 13,300 rpm for 10 min and finally resuspended in 100 µl water. Then 100 µl 
chloroform/phenol/isoamylalcohol (25:24:1) was added and phase separation was 
achieved using PhaseLockGel tubes at 13,300 rpm for 10 min at 4°C. Upper phase 
was transferred into new reaction tubes and DNA was precipitated with 10 µl 3 M 
NaOAc and 300 µl EtOH for 30 min at -20°C and centrifugation at 13,300 rpm for 15 
min at 4°C. Pellet was then washed with 500 µl 70% EtOH and pellet was 
resuspended in water. 
2.5.9. RNA Isolation 
Samples were harvested and 1 ml Qiazol (Qiagen) was added. Tissue samples were 
homogenized with an electric homogenizer. Then 200 µl chloroform were added and 
vortexed for 15 sec and incubated for 3 min. Phase separation was achieved by 
centrifugation with 3,500 rpm for 15 min at 4°C. The RNA containing upper phase 
was transferred into a new reaction tube and RNA was precipitated with 1 ml 
isopropanol and pelleted via centrifugation with 3,000 rpm for 10 min at 4°C. Pellet 
was washed with 70% ethanol at 2,500 rpm for 5 min at 4°C and then air-dried. It 
was then resuspended in 87.5 µl water and DNA digestion has been performed 
adding 10 µl DNaseI buffer and 2.5 µl DNaseI (NEB) for 30 min at RT. Then 250 µl 
ethanol were added and the RNA was purified with the RNeasy Mini Kit from Qiagen 
according to the protocol. 
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2.5.10. Measuring DNA and RNA concentration 
DNA or RNA concentration was measured with a NanoDrop1000 (PEQLAB) using 1 
µl of the solution.  
2.5.11. Quantitative Real-time-PCR (qRT-PCR) 
First, cDNA synthesis has been performed with the TaqMan kit (Applied Biosystems) 
or the PrimeScript RT MasterMix (Takara) according to the respective protocol. Then 
qRT-PCR was conducted using the SYBR Green Mastermix (Applied Biosystems) or 
SYBR Premix Ex Taq (Takara) according to the protocol on a 7300 Real Time PCR 
System (Applied Biosystem). Data was analyzed with the 7500 software (Applied 
Biosystems) using the 2(-∆∆Ct)-method. 
2.6. Biochemical methods 
2.6.1. Protein Isolation 
Samples were harvested and 500 µl NP40 buffer has been added. Tissues were 
additionally homogenized using an electric homogenizer. The mix was incubated on 
ice for 15 min while vortexing every 5 min. It was then centrifuged at 13,300 rpm for 
30 min at 4°C and the protein containing supernatant was transferred into a new 
reaction tube.  
2.6.2. Measuring protein concentration 
Protein concentrations were measured with the DC Protein Assay from Biorad 
according to the manufacturer’s protocol. 
2.6.3. Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE) 
To separate proteins according to their molecular weight SDS-PAGE has been 
performed using the Mini-PROTEAN Tetra Vertical Electrophoresis Cell device from 
Biorad. First SDS gels were cast according to the following table: 
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Table 6 composition of separating and stacking gel 
separating gel stacking gel 
Total 10 ml Total 2.5 ml 













10% SDS 100 µl 10% SDS 25 µl 
10% APS 50 µl 10% APS 12.5 µl 
TEMED 15 µl TEMED 7.5 µl 
 
Gels were put into the chamber which was filled with 1x running buffer. Then 30 µg of 
protein was mixed with 1/5 (v/v) 5x Laemmli buffer and filled up to 30 µl. Samples 
were incubated at 95°C for 10 min and loaded on the gels. SDS-PAGE was run at 
80V and maximum ampere until samples reached the separating gel. Then voltage 
was increased to 120 V. 
2.6.4. Western Blot 
Western blot was performed with a semi-dry or wet blot device. First, PVDF 
membranes were activated with MetOH for 1 min. Then, Whatman paper, PVDF 
membranes and gels were incubated in semi-dry or wet buffer, respectively, for 5 
min. Blotting sandwich was arranged in the respective order according to the device. 
Semi-dry blot was run at 17 V for 35 min at RT and Wet blot at 100 V for 90 min at 
4°C. Membranes were then incubated with blocking solution for 1 h at RT and then 
incubated with primary antibody o/n at 4°C. Next day, samples were washed three 
times with PBST for 5 min each and incubated with HRP-coupled secondary antibody 
for 1 h at RT. Membranes were again washed three times with PBST and specific 
signal were developed using Clarity Western ECL Substrate (Biorad) and a 
ChemiDoc Imaging System from Biorad. 
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2.7. Next Generation Sequencing (NGS) techniques 
2.7.1. Whole exome sequencing (WES) 
DNA from LCM purification was extracted using QIAamp MicroKit (Qiagen) according 
to the manufacturer’s protocol. DNA was fragmented using an ultrasonicator and 
libraries were prepared with the KAPA Hyper Library Prep Kit (PEQLAB). Adapter 
ligation was performed with Agilent SureSelect Oligo-Mix followed by PreCapPCR 
according to the KAPA Hyper Library Prep Kit protocol. Library was enriched with 
AllExon XT Target Enrichment Kit (Agilent) and samples were run on a HiSeq2500.  
2.7.2. Assay for Transposase-Accessible Chromatin (ATAC)-seq 
50,000 cells were pelleted at 500g for 5 min at 4°C and washed with cold PBS. 
Nuclei were extracted with ATAC lysis buffer and centrifuged at 500g for 5 min at 
4°C. Tagmentation was performed in 1x TD buffer (Illumina) and 2.5 µl Tn5 
transposase (Illumina) in a total volume of 50 µl for 30 min at 37°C. DNA was purified 
using MinElute Kit (Qiagen) and libraries were PCR-amplified for 14 cycles using 
NEBNext High-Fidelity polymerase (NEB) and subsequently purified with PCR 
CleanUp Kit (Qiagen). Samples were then sequenced on a HiSeq2000. 
2.7.3. Microarray gene expression profiling 
RNA from cells was prepared with GeneChip WT PLUS Kit (Affymetrix) according to 
the manufacturer’s protocol. Then GeneChip Hybridization, Wash and Stain Kit 
(Affymetrix) was used for further processing with Mouse Gene 2.0 ST Array 
(Affymetrix) according to the manufacturer’s protocol. Chips were scanned with an 
Affymetrix GeneChip Scanner 3000 7G. 
2.7.4. Chromatinimmunoprecipitation (ChIP)-seq 
10 million cells were each aliquoted into 15 ml cell culture medium and cross-linked 
with 1% PFA for 10 min at RT. Then, 1 ml of 2 M glycine was added to quench the 
reaction for 5 min at RT. Cell Signaling SimpleChip Kit including Micrococcal 
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Nuclease was used to isolate and digest chromatin following manufacturer’s protocol. 
Immunoprecipitations was conducted with equivalents of 40 million cells according to 
Cell Signaling ChIP protocol. ChIP-seq libraries were then generated using Accel-
NGS 2S Plus DNA Library Kit (Swift Biosciences) with an adjusted protocol were 
DNA purification was achieved with phenol/chloroform/isoamylalcohol (25:24:1) 
purification and precipitation with ethanol o/n. Enrichment of libraries was conducted 
with Agencourt AMpure beads with a 1.1:1 ratio of beads to DNA. Libraries were then 
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3. Results 
3.1. Hepatocyte-derived HCC and ICC can be induced by the same oncogenic 
drivers 
Mosaic cancer mouse models are highly tractable non-germline genetically 
engineered mouse models. To study liver cancer in such models we used the well-
established sleeping beauty (SB) transposon system112-114. This allows for stable 
integration of transposable elements into any host genome. These transposable 
elements can be genetically manipulated to encode for any gene of interest or 
shRNA cassettes to efficiently knockdown expression of specific genes via RNAi 
technology. As many human PLC patients harbor c-myc amplifications or activation 
of the MEK-ERK or PI3K pathway we used transposable elements encoding for c-
myc and a constitutively active NrasG12V (pCaMIN) or c-myc and a constitutively 
active myristoylated AKT-1 (pCaMIA, Fig. 7a)115-117. We then delivered these 
plasmids into p19-/- mice via HDTV together with an SB13 to stably transfect 
hepatocytes. After 3 to 4 weeks we could observe outgrowth of multifocal tumor 
across the whole liver (Fig. 7b). Although this mostly resembles the situation in 
human patients many of them also only develop single (unilocular) tumors. To also 
induce such single tumors in our studies, we took advantage of another hepatocyte-
specific delivery method, in vivo electroporation118. Indeed, Epo-induced delivery of 
pCaMIN or pCaMIA into livers of p19-/- mice allowed for outgrowth of single tumor 
nodules at the electroporated area after 4 to 6 weeks (Fig. 7c).   
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Figure 7 HDTV or Epo of c-myc/NrasG12V or c-myc/AKT-1 into p19
-/- mice induces tumor development (a) 
Schematic presentation of transposon vectors including pCaggs promotor, c-myc, an IRES, Nras
G12V
 and a 
polyadenylation site (pA) flanked by inverted repeats (IR), upper panel (pCaMIN), vectors including pCaggs 
promotor, c-myc, an IRES, AKT-1 and a polyadenylation site (pA) flanked by inverted repeats (IR), middle panel 
(pCaMIA) or transposase vectors including phosphoglyceratkinase (PKG) promotor, SB13 coding sequence and a 
pA signal, lower panel. (b) Schematic presentation of HDTV (upper panel) which induces multifocal tumors with 
pCaMIN and pCaMIA (lower panel. (c) Schematic presentation of Epo (upper panel) which induces single tumors 
with pCaMIN and pCaMIA (lower panel). 
Next, we sought to analyze the histopathology of the induced tumors. They were 
harvested, paraffin embedded and cut into 4 µm slides using a microtome. H&E 
staining of HDTV derived tumors showed typical HCC structures with solid or 
trabecular growth pattern and high steatosis (Fig 8a). Immunohistochemistry staining 
for the hepatocyte specific transcription factor HNF4alpha revealed strong nuclear 
signals while the biliary cell and cholangiocellular carcinoma specific marker K19 was 
totally absent (Fig. 8b and c). Taken together, HDTV injection of pCaMIA in all eleven 
mice and pCaMIN in all 14 mice induced pure HCC development (Fig. 8d). However, 
H&E staining of Epo induced tumor nodules revealed predominantly outgrowth of ICC 
with high amount of tumor stroma and glandular tumor cell formation (Fig. 8e). 
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HNF4alpha was mostly absent in these tumor while glandular structures were K19 
positive (Fig. 8f and g). Out of 19 mice injected with pCaMIA via Epo one developed 
pure HCC, seven developed pure ICC and eleven developed mixed HCC-ICC 
tumors. In the pCaMIN cohort out of 8 mice one developed pure HCC, three 
developed mixed HCC-ICC tumors and four developed pure ICC (Fig. 8h). 
 
Figure 8 Delivery method dependent tumor type development (a-c) Representative photograph of (a) H&E (b) 
HNF4alpha IHC or (c) K19 IHC stained sections of liver tumors derived by HDTV of pCaMIA (left panel) or 
pCaMIN (right panel) after 4 weeks . Scale bar = 100 µm. (d) Histopathological classification of 11 pCaMIA and 14 
pCaMIN HDTV derived tumors. (e-g) Representative photograph of (e) H&E (f) HNF4alpha IHC or (g) K19 IHC 
stained sections of liver tumors derived by Epo of pCaMIA (left panel) or pCaMIN (right panel ) after 6 weeks. 
Scale bar = 100 µm. (d) Histopathological classification of 19 pCaMIA and 8 pCaMIN Epo derived tumors. 
Several studies aimed to identify the cell of origin for HCC or ICC development, 
however, the results are still controversial. It has been shown that HDTV and Epo 
both target hepatocytes with high efficacy118, 119. However, to rule out the possibility 
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that the observed differences in the tumor type are due to targeting of other cells in 
the liver, we generated a lineage-tracing mouse model. We crossed ROSAmT/mG mice 
endogenously expressing membrane-tomato which switches to membrane-GFP 
expression upon Cre-recombination with AlbCre expressing Cre-recombinase under 
the hepatocyte specific albumin promotor120-122. These mice then were crossed into a 
p19-/- background to allow for tumor induction after intrahepatic transposon delivery 
(Fig. 9a). To test the functionality of these mice livers were harvested and 
cryosections of 6 µm were prepared for endogenous fluorescence imaging. While 
only hepatocytes had a green fluorescence all other cell types as bile duct cells or 
endothelial cells showed red fluorescence confirming the specificity of this lineage 
tracing model (Fig. 9b). We then delivered pCaMIN into these mice via HDTV or Epo 
and 4 or 6 weeks later tumors were collected. H&E and IHC stainings for HNF4alpha 
or K19 again showed HCC development upon HDTV and ICC development upon 
Epo, respectively (Fig. 9c). Endogenous fluorescence staining revealed that the 
HDTV derived tumors were all GFP positive (green) showing a hepatocytic origin. 
The Epo derived glandular tumors also showed pure GFP expression confirming that 
both tumor types derive from hepatocytes. Of note, the tumor stroma still showed 
tomato fluorescence (red) (Fig. 9d). To verify that the GFP positive glandular 
structures are indeed the K19 positive tumors we performed IF staining after 
quenching endogenous tomato signal. Indeed, the glandular structures showed 
endogenous GFP (green) expression co-localizing with K19 (red) signal (Fig. 9e).  
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 mice showing hepatocytes with GFP positive (green) membranes, bile duct and endothelial cells 
with tomato positive (red) membranes and DAPI (blue) stained nuclei. Scale bar, 100 µm (c and d) Photographs 
of H&E, K19 IHC, HNF4alpha IHC and native immunofluorescence stainings from liver tumors derived by pCaMIN 
HDTV (upper panel) or Epo (lower panel) in ROSA
mT/mG 
x AlbCre x p19
-/-
 mice. Scale bar, 100 µm (e) IHC staining 
of K19 (red) on liver tumors derived by pCaMIN Epo in from R ROSA
mT/mG 
x AlbCre x p19
-/-
 mice co-localized with 
GFP positive (green) tumors and counter stained nuclei with DAPI (blue). Scale bar, 100 µm (upper panel), 20 µm 
(lower panel). 
3.2. Lineage commitment in PLC is independent of somatic mutations 
Although HCC and ICC share similarities in their mutational landscape there are 
mutations which predominantly occur in HCC (e.g. TERT or CTNNB1) or ICC (e.g. 
IDH1/2, FGFR2-fusions), respectively5. To analyze if somatic mutations might 
influence the decision for HCC or ICC development in our model we aimed to 
perform whole exome sequencing (WES). First, mice were electroporated with 
pCaMIN and derived tumors were harvested. One half of every tumor was snap-
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frozen and the other half was conducted for histopathological analysis. To minimize 
inter-specimen background signal in the WES we selected tumors which had mixed 
HCC and ICC compartments to directly compare both tumor types. The according 
snap-frozen parts were cut with a cryostat into 6 µm slices and stained with a fast 
stain protocol to minimize DNA degradation. Then we performed laser capture 
microdissection (LCM) to separate normal tissue (n=1), HCC tissue (n=3) and ICC 
glands (n=3) and performed WES using a low-input protocol (Fig. 10a). We identified 
12 somatic mutations occurring in at least one of the tumor samples as mutations in 
the hydrase function gene Car7 or the glycoprotein gene Dag1, however, they were 
found in HCC and ICC samples. In contrast, mutations in Smc3 were found in two 
ICC samples but were absent in HCC and Fam72a mutations were found in two HCC 
samples but were absent in ICC (Fig. 10b). Nevertheless, interrogation of the online 
databases COSMIC and cBioPortal did not reveal any correlation of these mutations 
to either HCC or ICC. We further cloned Fam72a cDNA into our transposable 
elements via AscI and AgeI and introduced the same mutation found in the WES 
(259G>T) with a mutagenesis kit. This mutated Fam72a or a control vector was then 
co-delivered with pCaMIN via electroporation into p19-/- mice (Fig. 10c). The 
developed tumors were then stained for K19 which revealed ICC development in 
control as well as mutated Fam72a injected mice (Fig. 10d).  
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Figure 10 Somatic mutations do not determine liver tumor phenotype  (a) Representative photographs of 
normal and HCC tissue (left panel) or ICC glands (right panel) before and after LCM of mixed HCC/ICC  tumors 
derived from pCaMIN Epo of p19
-/- mice. (b) Overview of mutated (red) and non-mutated (green) genes identified 
by WES of LCM purified tumor material from three different mixed HCC/ICC tumors. (c) Schematic representation 
of pCaMIN vector and transposon vector encoding for mutated Fam72a (259G>T, Fam72a
MUT
) co-delivered via 
Epo into p19
-/- mice. (d) Representative photographs of K19 IHC of tumors derived by pCaMIN plus control 
transposon or pCaMIN plus Fam72a
MUT
 transposon via Epo of p19
-/- mice. Scale bar, 100 µm. 
3.3. Physicochemical conditions of oncogene plasmid delivery method 
determine the tumor type 
We could show that HCC and ICC can derive from the same cell of origin and that no 
specific mutations determine the lineage commitment. So we reasoned that 
transposon integration levels due to the different delivery methods, HDTV or Epo, 
might differ and influence the cell fate. We isolated genomic DNA from HDTV or Epo 
induced tumors and performed qRT-PCR with transposon specific primers which bind 
in the CAG promotor and c-myc in the transposable element. As a reference we used 
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β-actin primers which bind the exon and the intron to ensure detection of genomic 
DNA. We could show that the Epo method induced a 1.44-fold increased integration 
compared to the HDTV (Fig. 11a). To equalize the integration levels we used another 
version of the sleeping beauty transposase SB10 which has been reported to have 
lower transposition efficiency. We electroporated p19-/- mice with pCaMIN and SB10 
and harvested the outgrown tumors. We again isolated genomic DNA and performed 
transposon specific qRT-PCR. Indeed, integration levels were equal to HDTV with 
SB13, however, histopathology and HNF4alpha and K19 stainings of Epo/SB10 
derived tumors still showed ICC characteristics (Fig. 11a and b). We hypothesized 
that the electroporation procedure itself might play a significant role. To test this we 
first applied HDTV with pCaMIN and two hours later performed a mock 
electroporation in the same mouse and collected outgrown tumors after two to three 
weeks (Fig. 11c). We observed multifocal tumor development across the whole liver 
and a distinct tumor at the electroporated area (Fig. 11d). Strikingly, when we 
performed histopathological analysis with H&E, HNF4alpha and K19 stained tumor 
sections we could observe ICC outgrown at the electroporated area (Fig. 11e) while 
the HDTV induced multifocal tumors were clearly identified as HCC (Fig. 11f).  
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Figure 11 Epo-associated conditions favor ICC development (a) qRT-PCR data for transposon specific 
integration from genomic DNA isolated from HDTV or Epo induced tumors with pCaMIN and SB13 or Epo 
pCaMIN SB10. n=3 each (b) Representative photographs of H&E, HNF4alpha IHC and K19 IHC staining from 
Epo pCaMIN SB10 induced tumors still showed ICC phenotype. Scale bar, 100 µm (c) Cartoon of functional 
validation experiment to determine the influence of Epo-associated conditions on HDTV induced HCC. (d) 
Macroscopic overview of HDTV derived tumors (arrows) with highlighted electroporated area (dashed circle) (e) 
Representative photographs of H&E, HNF4alpha IHC and K19 IHC staining from  tumors in mock electroporated 
area two hours after HDTV. Scale bar, 100 µm (f) Representative photographs of H&E, HNF4alpha IHC and K19 
IHC staining from tumors after HDTV. Scale bar, 100 µm  
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3.4. Immune cell composition during the pre-tumorigenic phase does not 
impact tumor phenotype 
At this point we had proved that the electroporation conditions themselves are 
sufficient to switch HCC development to ICC development. To further characterize 
these pre-tumorigenic conditions we wanted to know when tumor onset starts to 
define the pre-tumorigenic phase. So we performed time series analysis after 
pCaMIN injection via HDTV or Epo. Five days after delivery we could observe 
microtumors which already show ICC characteristic in the Epo treated mice and HCC 
characteristic in the HDTV treated mice using HNF4alpha and K19 IHC stainings 
(Fig. 12a, indicated by arrowheads). Based on this we focused on the three day time 
point after transposon delivery for analyses of the pre-tumorigenic stage. We first 
analyzed livers for any macroscopic signs. HDTV induced tissue damage across the 
whole liver while Epo only focally led to tissue damage. H&E sections of livers, 
however, revealed large eosinophilic areas of tissue damage and high amount of 
infiltrating immune cells in damaged areas in both conditions (Fig. 12b). 
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Figure 12 Characterization of pre-tumorigenic phase upon HDTV or Epo (a) Representative photographs of 
H&E, HNF4alpha IHC and K19 IHC staining from tumors five days after Epo  (left panel) or HDTV (right panel) 
already showing microcarcinomas (white arrowheads). Scale bar, 100 µm (b) Macroscopic and microscopic 
photographs of liver tissue three days after HDTV (left panel) or Epo (right panel) revealed hepatic damage and 
immune cell infiltrations. Scale bar, 100 µm 
It has been shown in different studies that liver specific stellate cells and Kupffer cells 
play important roles in liver damage29. To quantify these cell types in the pre-
tumorigenic phase we performed IHC staining for alpha smooth muscle actin (aSMA) 
a marker for activated stellate cells. However, there were no differences between 
HDTV and Epo treated mice (Fig. 13a). We further conducted IF for F4/80 a Kupffer 
cell marker. Again no differences between HDTV and Epo could be observed (Fig 
13b). To also functionally test the role of Kupffer cells in liver tumor lineage 
commitment we took advantage of clodronate which are small liposomes specifically 
killing macrophages and Kupffer cells. To test their efficiency we first treated mice 
with lipopolysaccharide (LPS) to induce macrophage and Kupffer cell infiltration and 
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additionally administered clodronate or control liposomes. Then we harvested the 
livers after one day and digested the tissue with collagenase and filtered the cell 
suspension through a nylon mesh to prepare single cell solutions. The cells were 
then stained with CD45 and F4/80 antibodies to specifically label Kupffer cells and 
analyzed via flow cytometry analysis. While the Kupffer cell population from mice 
treated with control liposomes was 9.19% the population from clodronate treated 
mice was reduced to 3.95% (Fig. 13c, upper panel). We then pre-treated another 
cohort of mice three days before pCaMIN Epo with control or clodronate liposomes 
and continued the treatment for 2 weeks. After additional 4 weeks we collected the 
tumors and analyzed IHC staining for HNF4alpha and K19, however, both groups 
showed ICC histopathology (Fig. 13c, lower panel).  
 
Figure 13 Amounts of Kupffer cells and stellate cells are equal after HDTV or Epo (a) Representative 
photographs and quantification of aSMA IHC on livers three days after HDTV (upper panel) or Epo  (middle panel). 
n=2 each, scale bar, 100 µm (b) Representative photographs and quantification of F4/80 (green) on livers three 
days after HDTV (upper panel) or Epo (middle panel) with nuclei counter stained with DAPI (blue). n=3 each, 
scale bar, 100 µm (c) Flow cytometry analysis of single cell suspension from digested liver tissue from mice 
treated with LPS and control liposomes (upper left panel) or LPS and clodronate (upper right panel) with F4/80 
and CD45 specific antibodies to detect Kupffer cells. K19 IHC and HNF4alpha IHC from liver tumors of mice 
50  Results 
   
 
treated with control liposomes (middle panel) or clodronate (lower panel) before and after Epo pCaMIN revealed 
ICC phenotype. Scale bar, 100 µm 
Then, we also expanded our analyses to other types of immune cells. We performed 
IHC stainings for T-cells (CD3), monocytes and neutrophilic granulocytes (Ly6G), B-
cells (B220) and antigen-presenting cells (MHCII) (Fig. 14a and b). Quantifications of 
stained area per field of view showed an overall higher number of Ly6G and MHCII 
positive cells, however, no difference between HDTV and EPO treated mice was 
detectable (Fig. 14c). For further analysis of subpopulations of immune cells we 
performed flow cytometry analysis. We characterized T-cells (CD45+, CD3+), helper 
T-cells (CD45+, CD3+, CD8-, CD4+) and killer T-cells (CD45+, CD3+, CD8+, CD4-) as 
well as monocytic immature myeloid cells (moIMC, CD11b+, Gr1low , Ly6C+, F4/80-) 
neutrophilic immature myeloid cells (NeuIMC, CD11b+, Gr1+, Ly6C-, F4/80-) and 
macrophages (macr., CD11b+, Gr1-, Ly6C-, F4/80+). Again, we did not see any 
difference between HDTV and Epo treated mice (Fig. 14d and e). 
 
Figure 14 Immune cell populations in the liver do not differ between HDTV or Epo treated mice  (a) 
Representative photographs of CD3 IHC, Ly6G IHC, B220 IHC and MHCII IHC of damaged liver tissue of mice 
treated with pCaMIN HDTV after three days. Scale bar, 100 µm (b) Representative photographs of CD3 IHC, 
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Ly6G IHC, B220 IHC and MHCII IHC of damaged liver tissue of mice treated with pCaMIN Epo after three days. 
Scale bar, 100 µm (c) Quantification of positive stained areas of samples from (a) and (b) did not show any 
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) from mouse liver three days after HDTV or Epo, 
respectively. n=3 each 
3.5. Hepatocyte cell death influences tumor fate 
As we could not detect any differences regarding intrahepatic immune cell infiltrations 
we put our attention towards the damaged liver tissue itself. It is known that hepatic 
cell death is a major factor in liver disease and liver tumor development so we 
quantified the amount of dying cells in the affected tissue69, 88-90, 123. We performed 
TUNEL assay on cryosections of HDTV or Epo treated mice 3 days after pCaMIN 
delivery. There was a high amount of TUNEL positive cells in the HDTV (69%±16%, 
green, indicated by white arrowhead) but also in the Epo treated livers (70%±18%, 
green, indicated by white arrowhead, Fig. 15a). To validate that dying cells were 
hepatocytes we repeated this assay in the ROSAmT/mG x AlbCre x p19-/- mice. Indeed, 
TUNEL positive (red) cells were hepatocytes shown by GFP positive (green) 
membranes (Fig. 15b). Although the amount of dying cells in both methods is equal 
there is still the possibility that the type of cell death might be different as TUNEL 
detects all types of cell death124. To prove this we extracted protein lysates from 
HDTV or Epo-treated mice after three days and performed western blot for the 
apoptosis marker cleaved caspase 3 and the necroptosis marker pMLKL. Lysates 
from HDTV-treated mice clearly showed cleaved caspase 3 staining while they had a 
low signal for pMLKL (Fig. 9c, left panel). The opposite was true for lysates from Epo-
treated mice which had low levels of cleaved caspase 3 and higher levels of pMLKL 
(Fig. 15c, right panel). Additionally we conducted IHC for RIPK3 and activated 
pRIPK3, another marker for necroptosis. While HDTV-treated mouse liver did not 
show any signal livers from Epo-treated mice showed clear staining for both (Fig. 
15d). Upregulation of Ripk3 was also confirmed via qRT-PCR from livers where Epo 
treatment induced a 2.17-fold increase compared to HDTV (Fig. 15e). Necroptotic 
cells are known to secrete high levels of DAMP´s so we sought to analyze these 
signatures in our mouse models75, 76. We performed a qRT-PCR based array for 84 
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different cytokines and receptors where we identified five down-regulated and 14 up-
regulated candidates in Epo vs HDTV-treated livers (Fig. 15f). We then wanted to 
know if this Epo-induced cytokine pattern is dependent on the Epo-induced 
necroptosis induction. As necrostatin-1 (Nec-1) is a potent inhibitor of necroptosis we 
pre-treated mice three days daily before applying pCaMIN Epo. Nec-1 treatment 
reduced the amount of TUNEL positive cells (Fig. 15 g and h) although there was a 
slight induction of apoptosis shown by an increase in cleaved caspase 3 signal (Fig. 
15i). Nevertheless, induction of necroptosis was efficiently decreased shown by the 
strong reduction of pMLKL intensity (Fig. 15j). We again performed the qRT-PCR 
based cytokine array and could show that out of the 14 Epo-induced candidates 12 
could be reduced upon Nec-1 treatment (Fig. 15k). Analysis of immune cell infiltration 
via IHC staining further showed a significant reduction of Ly6G positive cells in Nec-
1-treated compared to control mice (Fig. 15l). We pre-treated another cohort of mice 
with control or Nec-1 three days before pCaMIN Epo and continued the treatment for 
two weeks. After additional four weeks we collected the tumors and performed 
HNF4alpha and K19 IHC. Strikingly, the amount of K19 positive staining was greatly 
reduced in Nec-1 treated group while the number of HNF4alpha positive cells was 
significantly increased in the tumor tissue (Fig. 15m and n). 
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Figure 15 Necroptosis induction upon liver electroporation (a) Representative photograph of TUNEL (green, 
positive cells are indicated by white arrowheads) staining and quantification of damaged liver tissue of mice three 
days after HDTV (upper panel) or Epo (lower panel). Scale bar, 100 µm (b) Representative pho tograph of TUNEL 
(red) staining on livers from ROSA
mT/mG 




mice three days after HDTV (upper panel) or Epo (lower 
panel) showing co-localization with GFP positive (green) hepatocytes. Scale bar, 100 µm (c) Western Blot on 
lysates from liver of HDTV (left panel) or Epo (right panel) treated mice after three days for cleaved caspase 3, 
pMLKL, MLKL and the corresponding controls. n=3 pooled lysates per lane (d) IHC for pRIPK3 and RIPK3 on 
livers from mice three days after HDTV (upper panel) or Epo (lower panel), Scale bar, 100 µm (e) qRT-PCR for 
Ripk3 from livers of mice three days after HDTV or Epo showed a significant upregulation in Epo treated livers. 
n=4 each (f) Fold-change expression of genes which are <-1.5-fold decreased or >1.5-fold increased in Epo vs 
HDTV treated livers in qRT-PCR based cytokine and receptor array. n=2 each (g) Representative photographs of 
TUNEL (green) staining on livers of mice pre-treated with control (upper panel) or Nec-1 (lower panel) three days 
before Epo harvested three days after Epo. Scale bar, 100 µm (h) Quantification of TUNEL positive cells from (g) 
showed significant reduction in the Nec-1 pre-treated group compared to control. n=3 (control) and 4 (Nec-1) (h) 
Western Blot on lysates from liver of control treated (left panel) or Nec-1 treated (right panel) mice three days 
after Epo for cleaved caspase 3, pMLKL, MLKL and the corresponding controls. n=3 pooled lysates per lane (k) 
Normalized log2 fold-change expression of Epo-associated upregulated genes from (f) in Epo or Nec-1 pre-
treated plus Epo treated mice compared to HDTV treated mice. n=2 each (l) Quantifications of positive areas for 
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B220, CD3 Ly6G or MHCII IHC staining on livers of Epo or Nec-1 pre-treated plus Epo treated mice after three 
days. n=3 each (m) Representative photograph of K19 and HNF4alpha IHC on tumor samples derived from Epo 
pCaMIN of mice treated with control (left panel) or Nec-1 (right panel). Scale bar, 100 µm (n) Quantification of 
HNF4alpha positive cells per field of view in tumor tissues from (m) showed significant induction in the Nec -1 
treated group. n=4 each 
Although Nec-1 is a potent necroptosis inhibitor it also has some additional effects. 
Due to its ability to block the interaction of RIPK1 and RIPK3 it can influence all 
downstream pathways of these targets125. To analyze the role of necroptosis more 
specifically we took advantage of a genetic model. Mice with hepatocyte specific Cre 
expression (AlbCre) were crossed with floxed MLKL mice (MLKLfl/fl). MLKL is the 
most downstream target in the necroptosis cascade. Efficient Cre-recombination 
induced knockout of hepatocyte MLKL was validated via western blot. Therefore, 
livers of AlbCre positive or negative mice were perfused and hepatocytes were 
purified. Western blot analysis of protein lysates from these cells showed total 
absence of MLKL in the AlbCre positive cells while AlbCre negative cells still showed 
a signal (Fig. 16a). We then conducted Epo in the MLKLfl/fl x AlbCre+/- mice and 
prepared protein lysates from whole tissue of electroporated liver areas. While there 
was a weak band for MLKL we could not detect any pMLKL compared to MLKL wt 
mice (Fig. 16b). As we proved functionality of these mice we aimed for further 
functional and tumor development studies. However, transformed hepatocytes have 
to be p19 deficient to allow for efficient tumor development. To achieve a p19 
knockout in these cells we used the CRISPR/Cas9 technology. For functionality 
testing we co-delivered a plasmid encoding for Cas9n and an sgRNA against p19 
included in a CRISPR cassette (CCsgp19) together with pCaMIN and SB13 into wt 
mice. We could show that these mice also developed tumors after four to six weeks 
which was slightly increased compared to complete p19-/- mice (Fig. 16c). So, we 
electroporated MLKLfl/fl x AlbCre+/- or MLKLfl/fl x AlbCre-/- with pCaMIN and CCsgp19 
and harvested livers after three days. We again performed IHC stainings to quantify 
different immune cell types, however, we could not detect any difference in B220, 
CD3, Ly6G or MHCII positive cells (Fig. 16d). When we performed the qRT-PCR 
based cytokine array we could see that from the Epo-specific cytokines Pf4, CCL8, 
CCL6, CCL5, CCR1 and Aimp1 were reduced in MLKLf l/f l x AlbCre+/- mice compared 
to MLKLfl/fl x AlbCre-/- (Fig. 16e, green bars). Furthermore we set up another cohort of 
mice for tumor development. The tumors were analyzed for HNF4alpha and K19 IHC 
which showed that hepatocyte specific knockdown significantly increases the number 
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of HNF4alpha positive HCC cells in the tumors (Fig. 16f and g). To exclude the 
possibility that the Cre expression might be the reason for this switch we also 
electroporated MLKL wt x AlbCre+/- mice and analyzed the developing tumors. 
However, they were mostly HNF4alpha negative and K19 positive proving an ICC 
phenotype (Fig 16h). To validate that necroptosis directly impacts the tumor 
phenotype we used the bile duct ligation (BDL) method which was reported to induce 
necroptosis in the liver90, 126. Ten days after BDL or sham operation livers were 
harvested and analyzed for necroptosis induction. We could detect pRIPK3 protein 
expression by IHC in BDL conducted mice as well as induction of pMLKL by western 
blot (Fig. 16i and j). Therefore we performed BDL or sham operation in a second 
cohort and additionally conducted HDTV with pCaMIN and SB13. Tumors were then 
harvested and analyzed for HNF4alpha or K19 expression to determine tumor 
phenotype. While sham operated mice harbored pure HCC tumors BDL treated mice 
showed poorly differentiated K19 positive HNF4alpha weakly positive tumors 
classified as tumors with mixed hepatobiliary features (Fig. 16k). 
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Figure 16 Genetic inhibition of necroptosis induces an ICC to HCC development switch (a) Western blot for 
MLKL with lysates from purified hepatocytes of MLKLfl/fl x AlbCre+/- and MLKLfl/fl x AlbCre-/- mice proving 
efficiency of Cre-recombinase induced knockout. n=2 each (b) Western blot for pMLKL and MLKL with lysates 
from MLKLfl/fl x AlbCre+/- mice after Epo compared to HDTV or Epo of p19
-/-  mice (middle and left part of the blot 
is the same depicted in Fig. 9c). n=3 each, 2 individual experiments (c) Duration until tumor development until 0.5 
cm diameter in p19
-/- mice treated with pCaMIN Epo or wt mice with pCaMIN plus CCsgp19 Epo. n=7 each (d) 
Quantifications of positive areas for B220, CD3 Ly6G or MHCII IHC stainings  on livers of Epo treated MLKLfl/fl x 
AlbCre+/- and MLKLfl/fl x AlbCre-/- mice after three days. n=3 each (e) Normalized log2 fold-change expression 
of Epo-associated upregulated genes from Fig. 9f in Epo treated MLKLfl/fl x AlbCre+/- and MLKLfl/fl x AlbCre-/- 
mice after three days. Down-regulated genes are marked in green. n=2 each (f) Representative photographs of 
K19 and HNF4alpha IHC on tumors derived from Epo pCaMIN treated MLKLfl/fl x AlbCre-/- (left panel) and 
MLKLfl/fl x AlbCre+/- (right panel) mice. Scale bar, 100 µm (g) Quantification of HNF4alpha positive cells per field 
of view in tumors from samples in (f). n=5 each (h) Representative photographs of HNF4alpha and K19 IHC on 
tumors derived from Epo pCaMIN treated MLKL wt x AlbCre +/- mice (i) Representative photographs of pRIKP3 
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on liver sections of sham-operated (upper panel) or BDL-treated (lower panel) p19
-/-  mice after 10 days. Scale 
bar, 100 µm (j) Western blot for MLKL and pMLKL with liver lysates from sham -operated or BDL-treated p19
-/- 
mice after 10 days. n=3 pooled lysates per lane (k) Representative photograph of K19 and HNF4alpha IHC on 
sections of liver tumors derived from sham-operated plus pCaMIN HDTV-injected (left panel) or BDL-treated plus 
pCaMIN HDTV-injected mice. Scale bar, 100 µm 
Next, we were interested if these findings also reflect the situation in human liver 
cancer patients. We pre-selected 84 genes defining an apoptosis signature and 10 
genes defining a necroptosis signature (Appendix) and analyzed a cohort of human 
HCC and ICC expression data regarding these signatures. We found that HCC 
samples had an overall up-regulation of pro-apoptotic genes while anti-apoptotic 
gens were down-regulated compared to ICC samples. The opposite was true for 
necroptosis-related genes which were higher in ICC samples compared to HCC (Fig. 
17a). Of note, expression of one main regulator of necroptosis, RIPK3, was 
significantly higher in ICC samples compared to HCC (Fig. 17b). 
 
Figure 17 Human HCC and ICC tumors harbor distinct transcriptomic cell death signatures (a) 
Transcriptome data from human HCC and ICC were analyzed regarding pre-selected gene signatures (84 
apoptosis-related genes and 10 necroptosis-related genes). HCC samples showed higher expression (red) of pro-
apoptotic genes and lower expression (green) of anti -apoptotic genes compared to ICC samples (left panel). 
Necroptosis-related genes were higher in ICC samples (right panel). (b) qRT-PCR of the same cohort for RIPK3 
showed significant upregulation in ICC samples compared to HCC. 
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3.6. Toll-like-receptors are necessary for lineage commitment in liver 
tumorigenesis 
We identified that necroptosis is the predominant type of cell death occurring after 
electroporation which can also influence lineage commitment in liver tumor 
development. Further we showed that necroptosis is accompanied by a specific 
cytokine pattern in the microenvironment. The most prominent receptor classes for 
DAMPs are the toll-like-receptors (TLRs). They are widely expressed on immune 
cells, however, some subclasses can also be found on nearly every cell type75, 76, 127. 
To analyze the role of TLRs in our tumor model system we used mice which are 
deficient for TLR 2, 3, 5, 7 and 9 (TLR5x KO)128. We conducted these mice and 
syngeneic wt mice to Epo to test if the genotype alone affects necroptosis induction. 
Western blot with protein lysates of livers three days after electroporation showed 
that there is still induction of necroptosis in these mice (Fig. 18a). IHC analysis of 
B220, CD3, Ly6G and MHCII positive cells did not show any difference between 
TLR5x KO or wt mice (Fig. 18b). qRT-PCR based cytokine array showed that from 
the Epo-specific pattern Il1b, Pf4, CCL8, CCL6, CCR1 and Aimp1 were reduced (Fig. 
18c). Interestingly out of these six candidates five were also reduced when 
hepatocytic necroptosis was inhibited (compare Fig. 18c, green bars and Fig. 17e, 
green bars). Again, we electroporated a second cohort which we used for tumor 
development studies. IHC analyses for HNF4alpha and K19 revealed that in the 
TLR5x KO mice tumors consisted of significantly more HNF4alpha positive HCC 
parts than the syngeneic wt mice (Fig. 18 d and e). To specify which TLRs are the 
most important ones for this switch we also performed tumor development studies in 
TLR 2 and 4 double KO mice. As before the amount of HNF4alpha positive HCC 
parts was increased in tumors of KO mice compared to the wt group. As TLR 4 and 2 
can be expressed on hepatocytes as well as immune cells we aimed to narrow down 
the important host cell. We electroporated SCID/beige mice which lack the majority of 
the adaptive and immune system and again found an increase in HNF4alpha positive 
tumor cells compared to syngeneic controls (Fig. 18g). 
Results  59 
   
 
Figure 18 Toll-like-receptors contribute to cell fate decision in liver tumorigenesis  (a) Western blot for 
pMLKL and MLKL with liver lysates from TLR5x KO and p19
-/-
 mice three days after Epo. n=3 pooled lysates per 
lane (b) Quantifications of positive areas for B220, CD3 Ly6G or MHCII IHC stainings on livers of Epo TLR5x KO 
and wt mice after three days. n=3 each (c) Normalized log2 fold-change expression of Epo-associated 
upregulated genes from Fig. 9f in Epo treated TLR5x KO and mice after three days. Down-regulated genes which 
are also identified in Fig. 11e are marked in green. n=2 each (d) Representative photographs of K19 IHC and 
HNF4alpha IHC on sections of liver tumor derived by pCaMIN Epo of control (left panel) or TLR5x KO (right 
panel) mice. Scale bar, 100 µm (e) Quantifications of HNF4alpha positive cells per field of view in tumor sections 
from (d). n=4 (wt) or 3 (TLR5x KO) (f) Representative photographs of K19 IHC and HNF4alpha IHC on sections of 
liver tumor derived by pCaMIN Epo of control (left panel) or TLR2/4 KO (right panel) mice. Scale bar, 100 µm (g) 
Representative photographs of K19 IHC and HNF4alpha IHC on sections of liver tumor derived by pCaMIN Epo 
of control (left panel) or TLR2/4 KO (right panel) mice. Scale bar, 100 µm 
3.7. Lineage commitment in liver tumorigenesis is epigenetically regulated  
After having identified a role of the microenvironment for determining cell fate 
decisions in liver tumorigenesis we next sought to address by which cell intrinsic 
mechanisms ICC vs. HCC outgrowth is regulated. It has already been reported for 
other cell types that the microenvironment can influence the cellular fate via 
epigenetic regulations101. As we could already exclude the influence of somatic 
mutations between HCC and ICC tumors in our model we hypothesized that 
epigenetic regulations might play an important role. First, we aimed to validate that 
the HCC or ICC phenotypes are stably imprinted in the tumor cells. We performed 
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HDTV or Epo with pCaMIN in p19-/- mice and harvested the outgrown tumors. We 
digested them with collagenase/dispase and took the cells into culture. Via serial 
dilutions we then selected single cell clones from each tumor type. To verify that we 
only culture ICC cells from the Epo derived tumors we performed K19 IF staining. We 
only continued with K19 positive cells while all HCC cells from HDTV induced tumors 
were K19 negative (Fig. 19 a). We then injected the cells into the flanks of 
immunocompromised Rag2-/- mice (Fig. 12b). While the HCC cell grew as solid, K19 
negative tumors ICC cells induced tumors with stromal parts and K19 positive cells 
(Fig. 19b and c). As stability of the tumor phenotype was verified we analyzed the 
epigenetic landscape of these cells. From each tumor type we used two single cell 
clones from male and two single cell clones from female mice and performed ATAC-
seq. This technique allows analyzing the accessibility of chromatin regions due to its 
conformation129, 130. Density heatmap of differentially accessible chromatin regions 
clearly showed that all HCC cells clustered together while all ICC cells clustered with 
the opposite accessibility of 108 different chromatin regions (Fig. 19d). K-means 
clustering of normalized ATAC fragment confirmed that all HCC cells can be nicely 
separated from ICC cells (Fig. 19e). With the same cell lines we then conducted 
transcriptome analyses using microarrays. Again, all tumor specific cells clustered 
together when we analyzed differentially expressed genes between HCC and ICC 
(Fig. 19f). These data clearly indicate that ICC and HCC cells which derived from the 
same cell of origin (Fig. 9d and e) harbor different epigenetic and transcriptomic 
signatures. 
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Figure 19 Epigenetic signatures of tumor phenotype in HCC and ICC cells (a) Representative photograph of 
K19 (red) IF staining on cells isolated from pCaMIN HDTV (upper panel) or pCaMIN Epo (lower panel) –induced 
tumors. Scale bar, 100 µm (b) Cartoon showing experimental setup to examine capability of tumor cells to regrow 
with similar phenotype (c) Representative photographs of H&E or K19 IHC stainings of tumors derived by injection 
of HCC cells (upper panel) or ICC cells (lower panel) subcutaneously into Rag2
-/-
 mice. Scale bar, 100 µm (d) 
ATAC-seq density heatmap of differentially accessible chromatin regions in HCC (left panel) or ICC (right panel) 
cell lines. Peaks are ranked according to ICC vs HCC fold-change. Data for each gene are represented as 
smoothed normalized fragment pseudo-counts ± 1kb around the center of peaks. n=4 single cell clone lines each 
(e) Bi-clustering of pairwise Pearson’s correlations of ATAC -seq data from (d). (f) Heatmap depicting data from 
transcriptome analysis of HCC (left panel) and ICC (right panel) cel l lines. Up-regulated genes are presented in 
red down-regulated genes are presented in green. n=4 single cell clone lines each  
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An open accessible chromatin region is no guarantee for transcriptional activity as 
there are many other factors which influence transcription.91, 97 To identify genes with 
correlations between chromatin accessibility and gene expression we conducted 
comparative analyses of ATAC-seq and transcriptome data. We found that the 
chromatin region of the transcription factor Tbx3 was inaccessible in ICC cells while it 
was accessible in HCC cells (Fig. 20a, left panel). This correlated with gene 
expression which was higher in HCC cells compared to ICC cells which we also 
validated via qRT-PCR (Fig. 20a, right panel, Fig. 20b). Furthermore, analysis of a 
large cohort of HCC and ICC patients also showed that human HCC tumors express 
significantly higher amounts of Tbx3 compared to ICC tumors (Fig. 20c). Another 
candidate from the comparative analysis was the transcription factor Prdm5 which 
showed accessible regions in ICC cells while the HCC cells did not (Fig. 20d, left 
panel). Again, this correlated with gene expression which was significantly higher in 
ICC cells compared to ICC which was also validated via qRT-PCR (Fig. 20d, right 
panel, Fig. 20e). Using the same cohort of human patients we could also show that 
human ICC tumors had a significantly higher expression of Prdm5 compared to 
human HCC tumors (Fig. 20f).  
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Figure 20 Tbx3 and Prdm5 are enriched in HCC and ICC, respectively (a) Correlation between ATAC-
fragment counts (left panel) and gene expression (right panel) of Tbx3 in HCC and ICC cells. n=4 single cell clone 
lines each (b) qRT-PCR data for Tbx3 in HCC and ICC cells. Data is presented as relative mRNA expression. n=4 
single cell clone lines each (c) qRT-PCR data for Tbx3 in human HCC and ICC tumor samples. Data is presented 
as relative log2 mRNA expression. n=199 (d) Correlation between ATAC-fragment counts (left panel) and gene 
expression (right panel) of Prdm5 in HCC and ICC cells. n=4 single cell clone lines each (b) qRT-PCR data for 
Prdm5 in HCC and ICC cells. Data is presented as relative mRNA expression. n=4 single cell clone lines each (c) 
qRT-PCR data for Prdm5 in human HCC and ICC tumor samples. Data is presented as relative log2 mRNA 
expression. n=199 
3.8. Prdm5 and Tbx3 are key regulators of PLC lineage commitment 
Although we could prove a direct correlation of Prdm5 and Tbx3 epigenetic regulation 
and mRNA expression to ICC and HCC, respectively, we aimed to functionally test 
their impact on our tumor mouse models. First, we cloned shRNAs against Tbx3 or 
Prdm5 with XhoI and EcoRI into a retroviral vector consisting of a TRE3G promotor, 
GFP-coding sequence, mirE shRNA backbone, PGK promotor, puromycin resistance 
cassette, an IRES and an rtTA3 coding sequence (RT3GEPIR). After verification of 
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correct insertion of the shRNAs via Sanger sequencing vectors were transfected into 
Phoenix-Ampho cells via CaPO3 method. After cells secreted virus into the 
supernatant it was collected and used for infection of HCC cells (shRNA against 
Tbx3) or ICC cells (shRNA against Prdm5). Infected cells were selected with 
puromycin and shRNA expression was induced by adding doxycycline. After three 
days cells were harvested and RNA was isolated and conducted for qRT-PCR. For 
each gene the two shRNAs with the best knockdown were chosen (Fig. 21a 
shTbx3_1 and shTbx3_2 and Fig. 21b shPrdm5_1 and shPrdm5_2) and subcloned 
via XhoI/AscI and XhoI/MluI into pCaMIN. For additional overexpression of Tbx3 or 
Prdm5, respectively, we also cloned cDNA of Tbx3 (Tbx3 OE) or Prdm5 (Prdm5 OE) 
via AscI/AgeI or AscI/NheI into transposable elements. To mimic a high expression of 
Tbx3, as found in HCC cells, we first electroporated pCaMIN including a control 
shRNA (pCaMINshRen) into p19-/- mice. Immunohistopathology of derived tumors 
showed growth of solid undifferentiated HNF4alpha and K19 negative tumors (Fig. 
21c, left panel). When Tbx3 OE was co-delivered with pCaMINshPrdm5_1 via Epo 
into p19-/- mice outgrown tumors were still K19 negative but were more differentiated 
and had a slight induction of HNF4alpha positive cells (Fig. 21c, right panel). We then 
wanted to mimic the expression of Prdm5 as found in ICC cells in our HDTV model. 
We co delivered pCaMIN together with Prdm5 OE and analyzed outgrown tumors, 
however, there were still pure K19 negative, HNF4alpha positive HCC (Fig. 21d, left 
part). We then aimed to analyze the function of Tbx3 in HCC lineage commitment so 
we performed HDTV of pCaMINshTbx3_1 into p19-/-. Histopathologic analysis of the 
derived tumors again showed K19 negative, HNF4alpha positive HCC (Fig. 21d, 
middle part). Similar to the experiments before in the Epo model we also co-delivered 
pCaMINshTbx3_1 and Prdm5 OE into p19-/- mice via HDTV. Livers were again 
subjected to histopathological analysis which showed that these mice had tumors 
which were clearly HNF4alpha negative, K19 positive ICC with high amount of 
stromal parts (Fig. 21d, right panel). These results suggest that Tbx3 and Prdm5 act 
in concert to determine lineage commitment in liver tumorigenesis. 
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Figure 21 Functional validation of Tbx3 and Prdm5 (a) Knockdown efficiency testing via qRT-PCR of HCC 
cells stably transfected with control or 2 independent shRNA against Tbx3. Data are presented as residual mRNA 
expression compared to control. n=3 each (b) Knockdown efficiency testing via qRT-PCR of ICC cells stably 
transfected with control or 2 independent shRNA against Prdm5. Data are presented as residual mRNA 
expression compared to control. n=3 each (c) Representative photographs of HNF4alpha and K19 IHC on 
sections of liver tumors induce by Tbx3 OE plus pCaMINshRen (left panel) or Tbx3 OE plus pCaMINshPrdm5 
Epo of p19
-/- mice. Scale bars, 100 µm (d) Representative photographs of HNF4alpha and K19 IHC on sections of 
liver tumors induce by Prdm5 OE plus pCaMINshRen (left panel), pCaMINshTbx3 or Prdm5 OE plus 
pCaMINshTbx3 HDTV of p19
-/- mice. Scale bars, 100 µm 
After showing the importance of Tbx3 and Prdm5 in tumor fate decision we aimed to 
examine pathways which were affected by these transcription factors. As there are 
no publications showing the direct binding of Tbx3 or Prdm5 to specific gene regions 
in mice we performed ChIP-seq analyses. We chose two of the HCC single cell clone 
lines and two of the ICC single cell clone lines each. All chromatin interactors were 
cross-linked and chromatin was isolated and immunoprecipitation was performed 
with Tbx3 or Prdm5 antibody, respectively. Then, libraries were prepared and 
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sequenced and annotated peaks for each gene were plotted on a heatmap. This 
heatmap was nicely in concordance with the ATAC-seq heatmap generated earlier 
with these cell lines proving the robustness of both analyses (Fig. 22a and b). To gain 
further insights into direct and indirect targets of Tbx3 or Prdm5, respectively, we also 
performed functional experiments. The HCC cell lines were stably infected with Tbx3 
or control shRNAs and ICC cell lines with Prdm5 or control shRNAs as described 
before. Then, RNA was isolated and microarray analyses were performed. These 
data were correlated to the ChIP-seq results to identify gene which were directly or 
indirectly up- or down-regulated upon Tbx3 or Prdm5 knockdown, respectively (Fig. 
22c and d). Interestingly, among the most regulated genes for Tbx3 are 
developmental genes like Hhip, Dkk1 or Daam2 while for Prdm5 cell morphogenesis 
genes like Cdh6, Twist1 or Snai2 are highly regulated. 
 
Figure 22 Direct and indirect targets of Tbx3 and Prdm5 transcription factors (a) Correlation of ChIP-seq 
data (left panel) for Tbx3 and ATAC-seq data (right panel) in HCC cells. Data are presented as normalized read 
per million mapped reads and ranked according to average Tbx3 ChIP-seq signal. n=2 cell lines each (b) 
Heatmap of differentially expressed genes for up (yellow) and down (blue) –regulated genes either directly or 
indirectly in HCC cells with stable Tbx3 knockdown compared to HCC cells with stable control shRNA expression. 
n=4 (2 cell lines with 2 different shRNAs each) or 2 (1 control shRNA in duplicate) (c) Correlation of ChIP-seq 
data (left panel) for Prdm5 and ATAC-seq data (right panel) in ICC cells. Data are presented as normalized read 
per million mapped reads and ranked according to average Prdm5 ChIP-seq signal. n=2 cell lines each (b) 
Heatmap of differentially expressed genes for up (yellow) and down (blue) –regulated genes either directly or 
indirectly in ICC cells with stable Prdm5 knockdown compared to ICC cells with stable control shRNA expression. 
n=4 (2 cell lines with 2 different shRNAs each) or 2 (1 control shRNA in duplicate) 
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Using the correlated ChIP-seq and microarray data we performed functional over-
representation analyses with MSigDB canonical pathways which revealed regulation 
of pathways like Biological oxidation or developmental biology for Tbx3 while for 
Prdm5 Extracellular matrix organization, collagen formation or Erbb signaling could 
be identified. Interestingly, there was nearly no overlap of annotated pathway 
between Tbx3 and Prdm5 (Fig. 23a). Finally, we sought to address how Tbx3 and 
Prdm5 might be epigenetically regulated during pre-tumorigenic phase to impact the 
tumor cell fate. So we performed HDTV or Epo with p19-/- mice and took liver 
samples three days later. We isolated RNA and performed a qRT-PCR based array 
to detect expression of epigenetic modifiers. We found nine significantly up-regulated 
genes in Epo-treated mice from different enzyme classes like histone deacetylases 
(Hdac5), histone acetyltransferases (Ncoa1) or histone lysine methyltransferases 
(Ehmt1) (Fig. 23b). However, functional validation of these candidates needs to be 
done in the future. 
 
Figure 23 Tbx3 and Prdm5 downstream signaling (a) Functional overrepresentation analysis of pathways 
using MSigDB canonical pathways using expression data from Fig. 15b and d. Down-regulated pathways are 
drawn as red up-regulated pathways are drawn as green circles. Size of the ci rcles correlates to the p-value (b) 
Volcano-plot of qRT-PCR based array for chromatin modifiers using RNA from Epo vs HDTV-treated livers after 
three days. n=3 each 
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4. Discussion 
Primary liver cancer, predominantly represented by HCC and ICC, with its increasing 
incidences and high mortality rates, represents a major health problem1, 4. 
Epidemiological data revealed that chronic liver inflammation and liver damage are 
important risk factors for both cancer types, however, up to now it remained unclear 
why some patients with such conditions develop HCC while others develop ICC5, 8. It 
has been shown in different studies that both cancer types can evolve from liver 
progenitor cells or from hepatocytes46, 47, 49.  
Over the last years more and more mouse models to study either HCC or ICC were 
developed. Mostly genetically engineered mouse models were used to study the role 
of single genes or genetic interactions. Other models took advantage of chemically- 
or inflammation-induced chronic liver damage which finally results in liver cancer 
development131. Models pioneered in the Zender laboratory utilize transposon vectors 
together with intrahepatic delivery methods to transform hepatocytes in their natural 
environment113, 114, 118. These models have the advantage of being relatively fast and 
highly flexible.  
 
In mosaic mouse models the use of defined driving oncogenes or combinations of 
oncogenic drivers usually triggers the outgrowth of either pure HCC or ICC. For 
example activation of the Wnt/β-catenin pathway which is often seen in human HCC 
and forced induction of the pathway also results in HCC in mice.132, 133 Conversely, 
Kras or Notch signaling, which is activated in human ICCs, also induces ICC 
development in mosaic mouse models49, 50, 134-136. These data suggest that 
oncogenic mutations can direct cell fate decisions in liver tumorigenesis. However, 
data obtained within the scope of the cancer genome project revealed a shared 
mutational landscape of many HCC and ICC, making it unlikely that phenotype-
specific mutations are the sole determinant of lineage commitment in liver cancer34-37. 
For example, besides mutations in the TP53 tumor suppressor, HCC and ICC share 
recurrent mutations in ARID1A, PIK3CA, MLL3, BAP1 and others34-37. Interestingly, 
in my thesis work we could show that overexpression of c-myc together with an 
NrasG12V mediated induction of the MEK-ERK signaling pathway or c-myc together 
with a constitutive active form of AKT1 can either lead to HCC, ICC or mixed tumors 
depending on the model of gene delivery. This led to the suggestion that other 
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factors than mutations also impact lineage commitment which is further supported by 
the fact that no additional somatic mutations occurred in our HCC or ICC model. Of 
note, lineage commitment in our model is determined at an early time point of 
tumorigenesis (5 days after oncogene delivery) while the spontaneous acquisition is 
a rather slow process.   
 
It has been under debate for several years which cells represent the cell of origin for 
HCC or ICC development. It has been shown via different lineage tracing models that 
HCC can derive from LPC or hepatocytes and that ICC can derive from LPC, 
cholangiocytes or hepatocytes43, 49, 137. However, it was not yet shown, that both 
cancer types can derive from the same cells in one model driven by the same 
oncogenes. Using the AlbCre hepatocyte-specific lineage tracing mouse model we 
could show that in our system HCC as well as ICC derived from adult hepatocytes. It 
has to be mentioned that some studies reported that in the AlbCre mouse an activity 
of Cre-recombinase was not only observed in hepatocytes but also in bile duct 
cells138. However, in concordance with our results, other showed hepatocyte-specific 
Cre-expression139. Furthermore it has been shown, that transformation via Epo only 
affects hepatocytes118. Nevertheless, to validate our results in another lineage-tracing 
model one could make use of a hepatocyte-specific adeno-associated virus 
expressing Cre under the Ttr promotor140. This virus which has been reported to 
express Cre exclusively in hepatocytes could be delivered into the ROSAmT/mG mice. 
Subsequently fluorescence analysis of Epo-induced ICC could validate hepatocytic 
origin of ICC tumors. However, our finding supports the theory that hepatocytes 
harbor a high grade of plasticity. Still, we do not know if hepatocytes first undergo 
dedifferentiation into PLC-like cells as it has been reported in other studies46. 
Interestingly, one study showed that hepatic injury is already sufficient for this 
dedifferentiation so it is likely that this may also occur upon Epo-treatment52. 
Immunohistochemistry analysis of stem cell markers as Nanog, Oct4 or Nestin could 
be conducted and analyzed to identify putative dedifferentiation of cells141. 
 
Many studies have shown that the microenvironmental conditions play a major role in 
tumor development. Using a sequential application of oncogene delivery via HDTV 
and a mock Epo clearly showed that environmental conditions due to Epo favor 
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development of ICC. The most prominent condition during the pre-tumorigenic phase 
in the HDTV as well as Epo model was the high amount of tissue damage.  
It is known that hepatic cell death is a prerequisite of liver cancer development69. It 
usually leads to proliferative compensation of other LPC or hepatocytes. Dying cells 
can release DAMP´s or other factors recruiting immune cells or directly interacting 
with normal or already transformed cells. Interestingly, in this study the type of 
hepatic cell death strongly depends on the oncogene delivery method. HDTV 
predominantly induces apoptosis which is reported in numerous studies to play major 
roles in HCC development. For example hepatocyte specific knockout of the BCL-2 
family member myeloid cell leukemia sequence 1 (MCL1) leads to high amounts of 
apoptosis-mediated liver damage subsequently resulting in HCC development142. 
Further, hepatocyte specific inhibition of the kinase TGF-β–activated kinase 1 (Tak1) 
showed high levels of cleaved caspase 3 again resulting in liver damage and HCC 
development143. It has to be mentioned that in these studies hepatic cell death is the 
driver of carcinogenesis while in our study it only seems to be a bystander of the 
delivery method. Chemical or genetic inhibition of apoptosis in our HCC model might 
help to answer the question if an apoptotic microenvironment is necessary for tumor 
development in general or even especially for HCC development.   
In contrast, induction of necroptosis could be observed after applying Epo to mouse 
livers. It is widely accepted and in accordance with our data that under physiological 
conditions hepatocytes do not express RIPK3 making them unlikely to undergo 
necroptosis. However, in line with our findings it has been reported that upon APAP, 
concanavalin A or high-fat-diet induced liver damage hepatocytes are able to induce 
Ripk3 expression144, 145. Necroptosis has not yet been directly linked to PLC 
development, however, there are several studies showing its importance in liver 
diseases which often subsequently develop into liver cancers. For example, 
increased levels of necroptosis have been described in liver disease patients. It was 
shown that expression of RIPK3 is induced in patients with ethanol-induced liver 
injury, cholangitis or NASH88-90. It is conceivable that the increased incidence of ICC 
might be, at least in part, due to the rising numbers of patients suffering from NASH. 
At least our study showed that necroptosis signatures are enriched in ICC patients. 
This data suggests that an anti-necroptotic therapy in liver disease patients might be 
able to reduce ICC induction or at least switch ICC to HCC development which is less 
invasive and for which more therapeutic options exist. Nevertheless, studies have to 
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be done in the future where liver disease patients with or without necroptosis marker 
need to be monitored for HCC or ICC development to draw a distinct correlation 
between necroptosis and ICC induction in humans.  
 
Another prominent observation in the microenvironment in the pre-cancerous phase 
of our PLC mouse models was the high amount of infiltrating immune cells. It is 
known from several studies that especially liver-resident immune cells as Kupffer 
cells and stellate cells highly impact development of primary liver cancers30, 31. 
However, this is mostly mediated by the induction of chronic liver damage or fibrosis 
which are pre-conditions for tumor development. It was also shown that Kupffer cell-
released tumor necrosis factor α (TNFα) directly induces biliary proliferation32. Other 
direct interactions of immune cells with oncogenically transformed cells have also 
been reported. For example it has been shown that immature myeloid precursor cells 
can inhibit NK cells which in turn promotes HCC development146. Interestingly, in the 
here presented study the composition of immune cell infiltrates seems to be irrelevant 
as no differences in numbers of any population could be observed between HDTV 
and Epo induction. This is quite interesting as necroptotic cells are known to release 
high amounts of pro-inflammatory DAMPs. Until now only few of them are known as 
IL-33, HMGB1 or ATP75. It is likely that they also play a major role in the Epo model, 
however, quantifications of these factors for example via western blot or functional 
studies using blocking antibodies during oncogenesis need to be done for validation. 
Nonetheless knockout of the most important DAMP receptors, the group of TLRs, 
was sufficient to favor HCC development over ICC. TLRs are especially widely 
expressed on cells of the immune system127. We further showed that in SCID/beige 
mice, which lack major parts of the innate and adaptive immune system 
predominantly also HCC develops after Epo-induced transformation. This suggests 
that TLRs on immune cells might be important mediators in the underlying 
mechanism that a necroptotic environment favors ICC development. However, it 
cannot be excluded that TLRs on hepatocytes also contribute. It is known that TLR4 
is expressed on hepatocytes and TLR2 can be expressed upon hepatocyte 
damage147, 148. Notably, knockout of these two TLRs is already sufficient to prevent 
necroptosis associated ICC development. Further, activated TLRs are known to be 
able to induce necroptosis76. Although there was an induction of necroptosis in 
TLR5x KO mice, there is still the possibility that hepatocyte-TLR-induced necroptosis 
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contributes to DAMP release which activates immune cell TLRs. This issue could be 
answered via bone marrow transplantation experiments from TLR knockout mice into 
wt mice or vice versa with subsequent Epo-induced tumorigenesis. Another approach 
would be to use hepatocyte or immune cell-specific TLR knockout mice for tumor 
development experiments. 
TLRs are also important in the activation of immune cells and not only in their 
attraction. Based on our results of quantifications of immune cells this might be more 
important in this study. This is supported by the fact that SCID/beige mice preferably 
develop HCC upon Epo-induced transformation. To characterize activity or 
maturation of immune cells flow cytometry with fluorescently labelled antibodies 
specific for maturation or activity markers could be conducted on liver lysates after 
applying HDTV or Epo. Functional experiments using immune cell-specific knockout 
mice or immune cell depleting treatments in HDTV- and Epo-induced tumor 
development and subsequent analysis of the tumor phenotype might also help to 
identify a putative role of immune cell activation. However, it has to be mentioned that 
in this study we used combinations with strong oncogenic drivers which are already 
sufficient to induce tumor development within the same time also in the absence of 
an intact immune system. So it remains possible that the role of immune cells in 
lineage commitment might be underestimated in this study as usually PLC develops 
due to inflammatory conditions69. To also analyze the influence of necroptosis in 
hepatocyte damage- or inflammatory-driven liver cancer mouse models utilizing DEN, 
CCl4 or concanavalin A could be used
131. In these models first chronic liver damage 
and inflammation occurs which subsequently induces HCC development. In parallel 
to the liver-damaging treatment chronic necroptosis induction could be applied. In 
such a setting long-term necroptosis-dependent immune reactions could be analyzed 
regarding the influence on HCC to ICC developmental switch. This would better 
reflect the situation in human patients were liver cancer develops over a long time 
with a more chronic necroptosis.   
Another hint suggesting that the activation status of immune cells influences lineage 
commitment comes from analyses of the cytokine milieu. We could show that 
necroptosis is associated with a distinct cytokine pattern and main sources for 
cytokine production are activated immune cells. In this study it was not addressed 
which distinct cytokine might be the most potent one to direct lineage commitment or 
how this regulations might be conducted. However, to identify these regulations is not 
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only important for understanding basic mechanisms but also holds high potential for a 
therapeutic modulation of cytokine effects. Indeed, it has been shown that single 
cytokines can regulate cancer development. For example interleukin 6 (IL-6) was 
reported to activate β-catenin pathway promoting HCC induction149. Although the 
cytokine analysis in Epo vs HDTV showed the highest regulation for CCL4, it is not 
much affected upon chemically or genetically inhibition of necroptosis. So, it is more 
likely that Epo-specific cytokines which were down-regulated upon necroptosis 
inhibition or TLR knockout, such as CCL6, CCL8, Pf4, or Aimp1 are important for 
lineage commitment. There are several possibilities to narrow down which distinct 
cytokines affect hepatocyte lineage commitment. First, hepatocytes could be isolated 
from HDTV or Epo-treated livers and expression of known cytokine-receptors could 
be analyzed. Further, phospho-proteomics could be conducted to identify activation 
of specific intracellular pathways which could be matched upstream to a cytokine 
receptor. Then functional experiments via blocking antibodies or applying 
recombinant cytokines in combination with HDTV or Epo of oncogenes could help to 
validate the results. Additionally, shRNA-mediated knockdown of cytokine-receptor 
downstream targets could also be applied simultaneously to oncogene delivery as 
well as over-activation via mutated cDNAs for genetic validation.  
Of course, not only the identification of the cytokine but also the determination of the 
cells which produce them might hold therapeutic potential. For example CCL8 is 
produced by macrophages or T-cells, however it is likely that also other cell types 
produce CCL8 as there is not much known about its sources yet150, 151. As 
SCID/beige mice lack functional T-cells and have impaired macrophages CCL8 might 
be an important regulator152. However, clodronate-mediated macrophage depletion 
did not switch ICC to HCC making macrophages the main regulatory cells more 
unlikely. CCL6 is also produced by macrophages as well as neutrophils which have 
decreased activity in SCID/beige mice153-155. Interestingly neutrophils also express 
multiple TLRs156. So there is the possibility that neutrophil derived CCL6 influences 
lineage commitment of liver cancer. Importantly, CCL6 could only be identified in 
rodents but not in humans so the human ortholog still needs to be identified for 
therapeutic use. Activated platelets are the only known source for Pf4 making them a 
putative candidate for lineage commitment, too. They also harbor TLR expression 
and it has been reported that SCID/beige mice have an impaired platelet function 
making platelet-derived Pf4 another putative regulator157, 158. About Aimp1 there is 
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not much known yet. It has been suggested that it is released from dying cells, 
however, there is no information about a specific immune cell population which 
releases Aimp1159. Nevertheless, to identify the source population or populations 
more functional experiments using depleting antibodies or knockout mice in our HCC 
and ICC models are needed. 
 
A key remaining question is which signaling pathways within the hepatocyte 
transduce the cytokine-mediated lineage commitment signals. As the information for 
tumor entity was heritable in tumor cells shown in cell transplantation experiments it 
is likely that epigenetic events might play an important role. Indeed, we found tumor 
type specific epigenetic signatures using chromatin accessibility analyses. It has 
been shown earlier that HCC and ICC harbor different epigenetic landscapes, 
however, in these studies it was not known from which cell types these tumors 
derived34, 108, 109. This is especially important as the normal epigenetic landscape 
between different cell types is already quite distinct. Also, the oncogenic drivers in 
these samples were quite diverse between all samples which made interpretation of 
the results difficult.  
It has been shown for cells in the hematopoietic lineage that environmental 
conditions can influence epigenetic landscape101, 102. One study used transplantation 
of bone marrow-derived macrophages into recipient mice and analyzed settled 
macrophages from different organs a few months later. Interestingly, they showed 
that epigenetic signatures from these transplanted macrophages were highly similar 
to distinct tissue-resident macrophages from control mice. How the interaction 
between the microenvironment and the macrophages could be conducted need to be 
remained. However, they found that especially some pioneer transcription factors 
have an altered methylation of the histone H3K4. Similar to this we could identify 
different chromatin accessibilities in gene regions of two pioneer transcription factors 
Tbx3 and Prdm5. 
Tbx3 is known to play important roles in cell stemness and especially in cell 
differentiation of LPC into hepatocytes or cholangiocytes. Deletion of Tbx3 reduces 
differentiation of hepatoblasts into hepatocytes but favors cholangiocytic 
differentiation160, 161. This correlates with the fact that in our study chromatin 
availability and expression of Tbx3 was significantly higher in HCC cells than in ICC 
as well as HCC patients compared to ICC. On the other hand, forced expression of 
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Tbx3 in our Epo-induced ICC model shifted tumor development towards phenotype of 
undifferentiated tumor. However, it remains unknown if forced Tbx3 expression only 
compensates necroptosis-associated cholangiocytic lineage differentiation or if it also 
able to switch already established ICC. This question could for example be 
addressed using inducible Tbx3 constructs using the TRE/doxycycline system. This 
would allow switching on Tbx3 expression via doxycycline food in mice already 
bearing ICC tumors.  
Importantly, knockdown of Tbx3 alone was not sufficient to switch HCC to ICC 
development. This might be explained with less efficient knockdown of Tbx3 as one 
study also showed that heterozygous knockout of Tbx3 had a much smaller 
developmental effect on the liver compared to homozygous knockout160. Experiments 
using the CRISPR/Cas9 system could be conducted to induce complete Tbx3 
knockout which might already be sufficient to alter tumor phenotype. 
Another pioneer transcription factor we identified using comparative analysis of 
ATAC-seq and microarray data was Prdm5. Prdm5 is known to attract histone 
methyltransferases or deacetylases and thus alter chromatin structure of bound 
genome regions162. Interestingly, expression of Prdm5 is associated with decreased 
activation of Wnt/β-catenin pathway which is usually activated in HCC163. This 
correlates with our findings that ICC cells as well as ICC patients have higher 
expression levels compared to HCC cells or patients, respectively.  
Nonetheless, forced expression of Prdm5 in our HDTV-based HCC model did not 
change the type of the tumor. One explanation for this observation could be that 
Prdm5 usually functions in concert with other transcriptions factors which might be 
less active in this scenario. However, simultaneous expression of Prdm5 together 
with Tbx3 knockdown was able to switch HCC- to ICC development. This was in line 
with the observation that downstream signaling pathways either related to Tbx3 or 
Prdm5 are quite distinct with only small overlaps. Interestingly, amongst positively 
related pathways to Prdm5 are collagen formation and extracellular matrix interaction 
which are important for interactions of tumor and stroma cells which are highly 
abundant in ICC3. 
Nevertheless, which exact downstream signaling events underlie the observed 
lineage commitment phenotype is still unknown. Taking advantage of our ChIP-seq 
and microarray data shRNA libraries could be generated and delivered together with 
a fluorescence marker into mice either via Epo or HDTV. Developing tumors could 
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then be harvested and sorted via flow cytometry with additional staining of K19 to 
differentiate between HCC and ICC tumor cells. Finally distribution of shRNAs could 
be calculated to identify main pathways for Tbx3 or Prdm5-mediated lineage 
commitment. 
A remaining question is how Tbx3 and Prdm5 itself are regulated during the early 
phases of tumor initiation. Our study suggested some candidates of chromatin 
remodeling proteins which are differentially regulated between HDTV and Epo in the 
pre-tumorigenic phase. However, functional validation of these candidates via 
additional overexpression or shRNA mediated knockdown of these regulators needs 
to be done in the future. To perform a more unbiased analysis oncogene delivery 
together with a marker gene should be performed and cells could be sorted via FACS 
at different time points. Transcriptome analyses or ATAC-seq might give insights into 
the dynamic and regulatory network of early epigenetic regulation. A more direct way 
would be a CRISPR-ChAP-MS analysis164. Here, sgRNAs specifically binding regions 
of Tbx3 or Prdm5, respectively, could be co-delivered with a Cas9 encoding plasmid. 
Then, bound Cas9 could be precipitated together with the chromatin and other bound 
factors. Subsequently, these factors could be analyzed via mass spectrometry to 
identify direct regulators of early Tbx3 or Prdm5 regulation. These putative 
candidates then need to be genetically validated if they indeed alter expression of 
Tbx3 or Prdm5.  
 
Our here presented findings on microenvironment dependent changes of the ICC or 
HCC defining epigenetic landscapes are likely to also have important implications for 
the treatment of HCC and ICC. It is well established that HCC and ICC behave quite 
different regarding therapeutic responses towards classical cytotoxic chemotherapies 
or molecularly targeted therapies. It has been shown that HCC represents a primarily 
chemoresistant tumor and so far no cytotoxic therapy could improve survival of 
patients with advanced HCC165. In contrast, ICC responds to cytotoxic therapy with 
the substances Gemcitabine and Cisplatin, resulting in a significantly increased 
survival of patients with advanced ICC28. Conversely, it was shown that treatment 
with the multikinase inhibitors sorafenib, lenvatinib and cabozantinib can moderately 
but significantly increase the overall survival of patients with advanced HCC, 
however, ICC do not respond to therapies with multikinase inhibitors20, 22, 166, 167. It is 
tempting to speculate that chromatin structural changes and epigenetic regulation 
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may contribute to these distinct patterns of sensitivity/resistance towards liver cancer 
therapies and may also contribute to acquired resistance in treated tumors. There are 
studies which show that HCC after a therapy using transarterial chemoembolization 
(TACE) with Doxorubicin show increased characteristics of cholangiocellular 
morphology168, 169. TACE is described to induce hepatic and tumor necrosis, 
however, there are no studies further characterizing the exact type of cell death170. 
Such an analysis could unravel the underlying mechanisms. If induction of 
necroptosis was observed, it would support our here presented theory of lineage 
commitment. Of course, only a direct correlation of TACE-induced necroptosis and 
subsequent ICC development could exactly validate it. Further, studies using anti -
necroptotic drugs during or after TACE might have therapeutic potential to reduce a 
switch to the more invasive ICC. Additionally, epigenetic analyses of tumors before 
and after TACE might be useful to support the here presented mechanism. Also 
combination therapies involving epigenetic modulators such as histone-deacetylase 
(HDAC) or methyltransferase inhibitors should be explored in order to break primary 
or secondary therapy resistance of liver cancer. Likewise, as ICC is highly metastatic 
while HCC most often show local destructive growth within the liver, such therapies 
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7. Appendix 
Apoptosis signature genes necroptosis signature genes 
APAF1 CRADD BIRC7 NFKBIB BIRC2 
BAD DAPK1 BIRC8 NFKBIE CASP8 
BAK1 DEDD BNIP3 NFKBIZ CFLAR 
BAX DEDD2 BNIP3L NLRP1 CYLD 
BBC3 DIABLO BOK NOD1 FADD 
BCAP31 FAS CARD18 NOD2 MLKL 
BCL10 FASLG CARD6 PEA15 RIPK1 
BCL2 HIP1 CARD9 PMAIP1 RIPK3 
BCL2A1 HRK CASP1 PYCARD TRADD 
BCL2L1 HTRA2 CASP10 REL XIAP 
BCL2L10 IFT57 CASP14 RELA  
BCL2L11 IKBKB CASP2 RELB  
BCL2L13 IKBKE CASP3 RIPK2  
BCL2L14 IKBKG CASP4 TBK1  
BCL2L2 LTA CASP5 TNF  
BCL3 LTB CASP6 TNFRSF10A  
BID MCL1 CASP7 TNFRSF10B  
BIK NAIP CASP8AP2 TNFRSF1A  
BIRC3 NFKB1 CASP9 TNFRSF1B  
BIRC5 NFKB2 CHUK TNFRSF21  
BIRC6 NFKBIA  TNFSF10  
 
